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Abstract 
Marine cyanobacteria has become one of the forefront and most studied areas in Marine Natural 
Products chemistry. In our country, the occurrence of massive proliferations of these 
microorganisms has been registered in San Andres and Old Providence Islands in the Colombian 
Caribbean Sea. Due to this, it was decided to investigate in first instance the toxicity of some of 
the species collected from this cyanobacterial blooms against Artemia salina, and also to evaluate 
their bioactive potential as source of antileishmanial and anticancer molecules, finding that most 
of the samples collected and evaluated were either toxic against A. salina or active against at 
least one of the cancer cell lines employed. According to the high toxicity exhibited in the brine 
shrimp bioassay, the extract of Oscillatoria nigroviridis was selected to carry out its chemical 
study in order to isolate the active compounds, being possible to identify six new compounds, 
termed almiramides D-I, together with the previously reported almiramide B. Neither 
almiramide B nor almiramide D were active against the antileishmanial bioassay. 
 
 
 
Key words: Marine cyanobacteria, CyanoHABs, toxicity, cytotoxicity, anticancer, bioactive 
compounds, non-ribosomal peptides. 
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Resumen 
Las cianobacterias marinas se han convertido en uno de los temas de vanguardia y en uno de los 
más investigados en la química de productos naturales marinos. En nuestro país se ha registrado 
la ocurrencia de proliferaciones masivas de estos microorganismos en las Islas de San Andrés y 
Providencia en el Mar Caribe Colombiano. Debido a esto, se decidió evaluar en primera instancia 
la toxicidad de las muestras recolectadas en estos afloramientos de cianobacterias contra 
Artemia salina, y también evaluar su potencial bioactivo como fuente de moléculas con actividad 
antileishmania y anticáncer, encontrando que la mayoría de las muestras evaluadas fueron tanto 
tóxicas contra A. salina como activas contra al menos una de las líneas celulares de cáncer 
empleadas. De acuerdo con la alta toxicidad mostrada en el ensayo de letalidad contra A. salina, 
se seleccionó el extracto de Oscillatoria nigroviridis para realizar su estudio químico, permitiendo 
la identificación de seis compuestos nuevos, provenientes de la ruta híbrida entre policétidos y 
péptidos no ribosomales denominados almiramidas D-I, junto con la almiramida B previamente 
reportada. Ni la almiramida B ni la almiramida D fueron activos en el bioensayo de antileishmania. 
 
 
 
Palabras clave: cianobacterias marinas, afloramientos algales nocivos de cianobacterias, 
toxicidad, citotoxicidad, anticáncer, compuestos bioactivos, péptidos no ribosomales. 
 
Contents XIII
 
 
Contents 
 Pag 
Abstract 
 
IX 
Resumen 
 
XI 
List of figures 
 
XV 
List of tables 
 
XVII 
List of symbols and abbreviations 
 
XIX 
Introduction 
 
1 
1. Chapter 1. Marine cyanobacteria as a promising and novel source of bioactive                    
                  natural products 
3 
1.1. Key role of natural products in drug discovery 3 
1.2. Marine Natural Products 4 
1.3. Marine cyanobacteria 11 
1.3.1. A glimpse on cyanobacteria 11 
1.3.2. Morphological diversity and classification 12 
1.3.3. Harmful Algal Blooms (HABs) 12 
1.3.4. Cyanotoxins 14 
1.3.5. Taxonomical origin of cyanobacterial bioactive compounds 16 
1.3.6. Structural classes of marine cyanobacterial compounds 19 
1.3.7. Metabolic building blocks 20 
2. Chapter 2: Evaluation of biological activity of marine cyanobacteria extracts  
                    collected at San Andres and Old Providence Islands 
25 
2.1. Introduction 25 
2.2. Bioactive natural products from marine cyanobacteria 26 
2.2.1. Marine cyanobacterial secondary metabolites as promising anticancer agents 26 
2.2.2. Pharmacologically neuroactive compounds from marine cyanobacteria 35 
2.2.3. Marine cyanobacterial compounds as anti-infective agents 37 
2.3. Experimental section 38 
2.3.1. Collection of cyanobacteria samples 38 
2.3.2. Extraction of samples 39 
2.3.3. Evaluation of toxicity of cyanobacterial extracts by Artemia salina lethality 
assay 
39 
XIV Contents 
 
 
2.3.4. Leishmanicidal activity of cyanobacterial crude extracts 39 
2.3.5. Evaluation of cytotoxicity activity against several cancer cell lines 40 
2.4. Results and discussion 41 
3. Chapter 3: Isolation and identification of compounds from the marine cyanobacterium 
                          Oscillatoria nigroviridis collected at San Andres Islands 
45 
3.1. Introduction 45 
3.1.1. Morphological description 45 
3.1.2. Chemistry of Oscillatoria genus 45 
3.2. Experimental section 53 
3.2.1. General experimental procedures 53 
3.2.2. Cyanobacterium collection 54 
3.2.3. Extraction and purification 54 
3.2.4. Evaluation of toxicity of extract fractions FI-FIX by Artemia salina lethality assay 55 
3.2.5. Leishmanicidal activity of fractions FI-FIX 55 
3.2.6. Evaluation of anticancer activity of fractions FI-FIX against several cancer cell 
lines 
55 
3.3. Results and discussion 56 
3.3.1. Structural elucidation of compound C1 56 
3.3.2. Structural elucidation of compound C2 61 
3.3.3. Structural elucidation of compounds C3-C5 63 
4. Conclusions and recommendations 69 
4.1. Conclusions 69 
4.2. Recommendations 70 
5. References 71 
A. Appendix: Optic microscopy photograph of Oscillatoria nigroviridis filaments. 81 
B. Appendix: 
1
H-NMR profiles of fractions FVII6-FVII8.  83 
C. Appendix: NMR and MS spectra of almiramide D. 85 
D. Appendix: NMR and MS spectra of almiramide B. 91 
List of figures XV
 
 
List of figures 
 Pag 
Figure 1.1: Total of new small molecule drugs, by source between 1981/01-2008/10. 4 
Figure 1.2: Percentage of cyanobacterial secondary metabolites by taxonomical order. 17 
Figure 1.3: Percentage of compounds isolated from marine cyanobacteria by genus. 18 
Figure 1.4: Number of cyanobacterial collections by location based on publications from 
                    January 2001 to December 2006. 
19 
Figure 1.5: Structural characterization of marine cyanobacterial natural products. 20 
Figure 1.6: Number of occurrence of amino acids in cyanobacterial natural products. 21 
Figure 1.7: Occurrence of modifications of amino acids typically found in marine 
                    cyanobacterial natural products. 
22 
Figure 1.8: Chirality of unmodified amino acids incorporated into marine cyanobacterial 
                    natural products. 
23 
Figure 1.9: Chirality of N-methylated amino acids incorporated into marine cyanobacterial 
                    natural products. 
23 
Figure 2.1: Comparison of global distribution of PSP toxins in 1970 and 2006. 26 
Figure 3.1: Percentage distribution of cyanobacterial metabolites obtained from 
Oscillatoria genus. 
46 
Figure 3.2: Isolation diagram employed for the purification of compounds C1 to C5. 55 
Figure 3.3: HPLC isolation chromatogram. XTerra® reversed phase column (RP-18, 250 × 
4.6 mm, 5 µm), isocratic mode 50% ACN/H2O acidified with 0.05% formic acid. 
56 
Figure 3.4: Substructures a-f of compound C1 showing COSY/TOCSY and HMBC 
correlations. 
60 
Figure 3.5: Linear structure of C1 established from key HMBC correlations and HRESIMS 
fragmentation 
60 
Figure 3.6: Substructures a-f of compound C2 showing COSY/TOCSY and HMBC 
correlations. 
62 
Figure 3.7: Planar structure of C5 determined by HRESIMS fragmentation. 63 
Figure 3.8: a. TIC obtained by LC-MS of C3; b. MS spectrum of C3.1; c. MS spectrum of 
C3.2. 
64 
Figure 3.9: Structure of almiramide E, deduced by MS fragmentation analysis. 64 
Figure 3.10: Structure of almiramide F (C3.2) based on MS analysis. 65 
Figure 3.11: MS analysis based structure for almiramide G (C4.1). 66 
Figure 3.12: Proposed structure for almiramide H. 66 
Figure 3.13: Structure of almiramide I by MS fragmentation analysis. 67 
List of tables XVII
 
 
List of tables 
 Pag 
Table 1.1: Status of the current pipeline of drugs derived from marine natural products. 5 
Table 1.2: Common cyanobacterial toxins. 15 
Table 2.1: Potent and promising anticancer compounds isolated from marine 
cyanobacteria. 
31 
Table 2.2: Pharmacologically neuroactive compounds from marine cyanobacteria. 36 
Table 2.3: Marine cyanobacterial secondary metabolites with promising anti-infective 
                   activities. 
37 
Table 2.4: Marine cyanobacteria strains collected at San Andres and Old Providence 
Islands. 
41 
Table 2.5: Results of the evaluation of biological activity of marine cyanobacteria extracts. 44 
Table 3.1: Secondary metabolites isolated from different species of Oscillatoria genus. 49 
Table 3.2: Results of the evaluation of biological activity of fractions FI to FIX from O. 
                   nigroviridis. 
58 
Table .3.3: 1D and 2D NMR data of compound C1 in CD3OD (
1H-NMR at 600 MHz; 13C-NMR 
                    150 MHz). 
59 
Table 3.4: 1D and 2D NMR data of compound C2 in CD3OD (
1H-NMR at 600 MHz; 13C-NMR 
                    150 MHz). 
61 
Table 3.5: Results of the evaluation of antileishmania activity of almiramides B and D. 67 
 
List of symbols and abbreviations XIX
 
 
 
List of symbols and abbreviations 
Symbol/abbreviation Term 
[α]D Optical rotation 
ADC Antibody-drug conjugate 
Ala Alanine 
Arg Arginine 
Asp Aspartic acid 
CDCl3 Deuterated chloroform 
CD3OD  Deuterated methanol 
CyanoHABs Cyanobacterial Harmful Algal Blooms 
Cys Cysteine 
COSY Correlation SpectroscopY 
DMSO Dimethyl sulfoxide 
EtOAc Ethyl Acetate 
EtOH Ethanol 
FCC Flash Column Chromatography 
Glu Glutamic acid 
Gly Glycine 
HABs Harmful Algal Blooms 
His Histidine 
HMBC Heteronuclear Multiple Bond Correlation 
HPLC High Performance Liquid Chromatography 
HRESIMS High Resolution Electro Spray Ionization Mass Spectrometry 
RP-HPLC Reversed Phase-High Performance Liquid Chromatography 
HSQC Heteronuclear Single-Quantum Correlation 
Ile Isoleucine 
J Coupling constant 
Leu Leucine 
Lys Lysine 
MeOH Methanol 
MNP Marine Natural Product(s) 
Moya 2-methyl-oct-7-ynioc acid 
MS-MS / MSn Tandem Mass Spectrometry 
MS Mass Spectrometry 
NMR Nuclear Magnetic Resonance 
NRP Nonribosomal peptide 
NRPS Nonribosomal peptide synthase 
XX List of symbols and abbreviations 
 
 
Phe Phenylalanine 
PK Polyketide 
PKS Polyketide synthase 
ppm Parts per million 
Pro Proline 
Ser Serine 
SPE Solid Phase Extraction 
Thr Threonine 
TOCSY Total Correlation SpectroscopY 
Tyr Tyrosine 
Val Valine 
VDA Vascular disrupting agent 
  
Introduction 
Undoubtedly Nature has been used as a source of therapeutic agents for the treatment of several 
diseases through history of human kind, establishing the basis for modern medicine. The impact 
of natural products is such big that from all the small molecules approved for use as drugs during 
the last three decades, around 70% of them are either inspired, or derived from natural products 
pharmacophores [1]. 
 
Although traditionally terrestrial plants have the most studies, since the late 1950s of the last 
century, natural products chemistry has been focused into the marine environment as a new and 
unexplored source, for the discovery of novel bioactive compounds, which makes sense since 
around 70% of the Earth´s surface is covered by oceans, hosting 34 out of the 36 phyla present in 
the whole planet. The efficacy of marine natural products has been proved in preclinical in vitro 
studies carried out by the National Cancer Institute (NCI), in which around 1.8% of crude extracts 
showed antitumor activity, compared to 0.4% active extracts of terrestrial origin [2, 3]. This high 
activity may be due to several factors in which can be highlighted the evolutionary advantage of 
marine organisms because of their longer time of existence, as life is considered to be originated 
from the seas. This implicates that sessile species have expended more time improving their 
chemical defenses in order to survive in a complex environment which can harbour a higher 
species densities that a tropical rainforest. These exceptional metabolic characteristics developed 
by marine organisms have made possible to obtain several current approved drugs for treatment 
of cancer, chronic pain and viral diseases, and some other compounds currently undergoing 
clinical trials [5]. 
 
Invertebrates such as sponges, corals, nudibranchs, ascidians, etc, have been the most studied 
source of marine natural products, but recently the attention has turned out into the marine 
microorganisms, as they have been found to be in symbiotic relationships with these 
macroorganisms becoming the real metabolic source of the bioactive compounds. Their potential 
also relies on the fact that, according to some calculations just around 0.01% to 0.1% of all marine 
microorganisms have been studied and identified [4], demonstrating the enormous and 
unexplored potential of these novel source, additionally to their unique and intriguing metabolic 
features. 
 
2 Introduction 
 
 
Among the most studied and promising microorganisms, are the marine cyanobacteria. These 
Gram-negative photosynthetic prokaryotes, capable of nitrogen fixation, have the ability to 
inhabit practically any environment from rocks, soil, freshwater or sea water, to endosymbionts, 
as well as extreme environmental conditions such as temperature, pressure, pH or salinity [18-
21]. Cyanobacteria are one of the responsible organisms of Harmful Algal Blooms (HABs), that 
when dominated by toxic species constitutes a serious risks for aquiculture and touristic activities, 
as well as for animal and human health, leading even to cause death. These toxic effects are 
caused by the production of potent toxins, which according to the target of action, are classified 
as hepatotoxins, neurotoxins and dermatotoxins. These events have been usually reported in 
freshwater ecosystems, but in recent years a notable increasing of this phenomenon in marine 
environments has been showed, mainly in tropical areas. This fact have been associated with 
increasing eutrophication of water, i.e. increment and overloading of nutrients mainly nitrogen 
and phosphorous, and pollution processes directly related to anthropogenic activities such as 
agriculture, industrial waste disposal and environmental factors like global warming which also 
facilitates massive proliferations of these microorganisms. 
 
Apart from the consideration of cyanobacteria as a nuisance problem, since three decades ago, 
these marine microorganisms have gained attention because of their relevant impact in the 
discovery of new pharmacologically active compounds, with a wide range of bioactivities which 
include anti-bacterial, anti-viral, anti-fungal, cytotoxic, anticancer, anti-infective, anti-
inflammatory [38, 41, 57, 58], leading even to be source of some of the approved anticancer 
drugs as brentuximab vedotin [8], or Soblidotin and Synthadotin which are currently undergoing 
phase III and phase II clinical trials, respectively [5]. Marine cyanobacterial metabolites, 
comprised mainly by polyketide-nonribosomal peptide hybrid compounds, are unique and 
characterized for having distinctive structural modifications such as N- or O-methylations, 
halogenations, extension of the lateral chain of the amino acids, incorporation of unusual 
polyketide extender units, presence of heterocyclic rings, α- or β-amino acids, and incorporation 
of D-enantiomeric amino acids, a reason on which relies the great bioactivity displayed by these 
secondary metabolites. 
 
Taking into account the previous overview and, that in Colombia there is certainty about the 
occurrence of cyanobacterial blooms is some areas of San Andres and Old Providence Islands, this 
investigation was directed to carry out toxicity studies of marine benthic cyanobacteria from 
Colombian Caribbean Sea with the aim to spread the chemical studies on local marine organisms. 
To achieve this, were carried out lethality bioassays against Artemia salina to evaluate the toxicity 
of the species involved, and by means of this bioassay perform a bioactivity guided isolation of 
one of the most toxic samples, to isolate and identify the possible active compounds. In 
conjunction with toxicity evaluation of cyanobacteria, were also carried out bioactivity screenings 
of the crude extracts as antileishmanial and anticancer tests, to evaluate their potential use and 
evaluation in subsequent chemical studies. These bioassays allowed to determine that most of 
the species collected have anticancer activity. Therefore, this work constitutes the first chemical 
investigation done in Colombia on marine cyanobacteria, and lays the groundwork for further 
investigations on this state-of-the-art subject. 
 
  
 
 
Chapter 1 
1. Marine cyanobacteria as a promising and novel 
source of bioactive natural products. 
 
1.1. Key role of natural products in drug discovery 
 
Nature has been the most successful source for the treatment of several diseases through history, 
leading to the discovery of relevant therapeutic agents and also serving for the inspiration of 
novel ones, laying the groundwork for modern medicine. Despite the decreased emphasis of 
pharmaceutical companies on natural products for drug discovery since the late 1980s to the 
beginning of 2000s, nowadays is clear their crucial role, in such way that, according with Word 
Health Organization (WHO) approximately 65% of the world´s population rely their healthcare on 
plant based medicines [1]. It has been such great the impact of natural products that the analysis 
for the total of 1024 new small molecule drugs during the period between 1981/01 to 2008/10, 
states that although 67% of the compounds are formally synthetic, just a small percentage of 37% 
is of truly synthetic compounds without any inspirational natural compound, and the remainder 
percentage have some inspiration on natural products. Considering diseases categories, anti-
infective agents area, i.e. anti-bacterials, anti-fungals, anti-parasitic and anti-virals, 68.3% of the 
compounds are naturally derived or inspired, and in the anti-cancer area 79.8% of the compounds 
are included in these categories, as is shown in figure 1.1 [1]. 
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Figure 1.1: “Total of new small molecule drugs, by source between 1981/01-2008/10 (N=1024; N, 
unmodified natural products; ND, modified natural products; S, synthetic compounds with no 
natural product conception; S/NM, synthetic compounds showing competitive inhibition of the 
natural product substrate; S*, synthetic compounds with a natural product pharmacophore; 
S*/NM, synthetic compounds with a natural product pharmacophore showing competitive 
inhibition of the natural product substrate).” Figure adapted from [1].  
 
1.2. Marine Natural Products 
 
Over the final decades of the last century, the study of natural products turned its attention into 
the sea as a new and unexplored source, which is logic, taking into account that around 70% of 
the Earth´s surface is covered by oceans. The results shown within this new area have proved to 
be successful in the discovery of new bioactive compounds, which characterize for both their 
unusual and unique structures, not found in their terrestrial counterparts, and for their potent, 
improved and widespread range of bioactivities. The efficacy of marine natural products has been 
proved in preclinical in vitro studies carried out by the National Cancer Institute (NCI), in which 
around 1.8% of crude extracts showed antitumor activity, compared to 0.4% active extracts of 
terrestrial origin [2, 3]. This greater bioactivity can be due to several considerations, for example 
because of the huge biodiversity existing in the oceans, which constitutes around 95% of the 
biosphere in which are present 34 of the 36 phyla in the world. Also because as life was 
originated in the sea, means that have more time evolving there, and finally, due to the 
evolutionary stress in the adaptation to these marine ecosystems, that may even have a higher 
species density than a tropical rainforest, therefore competitiveness favours species which 
evolves and improves its survival mechanisms, especially invertebrate and sessile species that 
lack physical defenses, thus its success lies in the development of a wide arsenal of chemical 
defenses [3]. 
 
Traditionally marine invertebrates such as sponges, soft corals, ascidians and others, have been 
the primary source of bioactive compounds, and though many compounds have been isolated 
since the first reports in the late 1950s, only a few compounds from marine origin have been 
approved and become drugs [4]. The current pipeline of marine compounds consist of 5 approved 
drugs by the FDA, named cytarabine (Cytosar-U®, Depocyt 1), vidarabine (Vira-A® 2), ziconotide 
(Prialt® 3), the halichondrin B derivate eribulin mesylate (Halaven® 4) and the antibody-drug 
conjugate brentuximab vedotin (SGN-35, Adcetris® 5), and ecteinascidin 743 (Yondelis® 6) 
registered by the European Agency for the Evaluation of Medicinal Products (EMEA) [4, 5]. 
Additionally to the approved marine drugs, there is a total of 11 compounds (7-17) undergoing 
different phases of clinical assays which are highlighted in table 1.1 [5]. 
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Table 1.1: Status of the current pipeline of drugs derived from marine natural products [5]. 
Compound Trademark 
Marine 
organism 
Disease 
area 
Clinical 
status 
 
1 Cytarabine, Ara-C 
Cytosar-U® Sponge Cancer Approved 
 
2 Vidarabine, Ara-A 
Vira-A® Sponge Antiviral Approved 
 
3 Ziconotide 
Prialt® Cone snail Pain Approved 
 
4 Eribulin mesylate (E7389) 
Halaven® Sponge Cancer Approved 
5 Brentuximab vedotin (SGN-35) 
Adcetris® Bacterium Cancer Approved 
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6 Trabectedin (ET-743) 
Yondelis® Tunicate Cancer 
Approved 
(EU 
registere
d only) 
 
7 Soblidotin (TZT 1027) 
NA Bacterium Cancer Phase III 
 
8 DMXBA (GTS-21) 
NA Worm 
Cognition 
Schizoph
renia 
Phase II 
 
9 Plinabulin (NPI-2358) 
NA Fungus Cancer Phase II 
 
10 Plitidepsin 
Aplidin® Tunicate Cancer Phase II 
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11 Elisidepsin 
Irvalec® Mollusk Cancer Phase II 
 
12 PM00104 
Zalypsis® Nudibranch Cancer Phase II 
 
13 Tasidotin, Synthadotin (ILX-651) 
NA Bacterium Cancer Phase II 
 
14 Pseudopterosin A R1, R2, R3 = H 
NA Soft coral 
Wound 
healing 
Phase II 
 
15 Bryostatin 1 
NA Bryozoan Cancer Phase I 
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16 Hemiasterlin (E7974) 
NA Sponge Cancer Phase I 
 
17 Marizomib (Salinosporamide A) 
NA Bacterium Cancer Phase I 
NA: not applicable. 
 
Although the first marine-origin compounds were isolated in 1951, was not until 1969 and 1976 
that Ara-C (1) (an anti-leukemia agent) and Ara-A (2) (an antiviral agent), were approved by FDA 
respectively, as chemical derivates of the originally isolated nucleosides from the Caribbean 
sponge Tethya crypta [4, 5]. Cytarabine (Ara-C 1 or arabinosyl cytosine) is a synthetic pyrimidine 
nucleoside developed from spongothymidine. Ara-C is an S-phase specific cytotoxic agent, which 
competes with the physiologic substrate deoxycitidine triphosphate, resulting in the inhibition of 
both DNA polymerase and DNA synthesis [5]. 
 
Vidarabine (Ara-A 2 or adenine arabinoside) is a synthetic purine nucleoside analogue of 
spongouridine, which is currently isolated from Streptomyces antibioticus. Ara-A inhibits viral 
DNA polymerase and DNA synthesis of herpes, vaccinia and varicella viruses, when is converted 
into adenine arabinoside triphosphate [5]. 
 
Since the approval of these two nucleosides, passed almost 30 years until the next marine natural 
product (MNP) was approved. Ziconotide (Prialt® 3) was approved in the United States in 2004, 
for treatment of chronic pain. Ziconotide is the synthetic equivalent of the natural ω-conotoxin 
MVIIA isolated from the venom of fish-hunting cone snail Conus magnus. ω-conotoxin MVIIA is a 
linear policationic peptide linked by three disulphide bridges of the six cysteine residues [6]. This 
compound characterizes by its novel mechanism of action, reversibly blocking N-type voltage 
sensitive calcium channels on primary nociceptive afferent nerves in the superficial layers of the 
dorsal horn of the spinal cord [5]. 
 
Eribulin mesylate (E7389 or Halaven® 4) is a compound based on the pharmacophore structure of 
naturally occurring polyether macrolide compound halichondrin B. This MNP, was first isolated in 
the minor fractions of extracts of the sponge Halichondria okadai, in conjunction with other 
related halichondrins, which showed to have potent cell inhibitory activity at nanomolar range (~ 
1x10-9 M). The structural complexity did not make possible obtaining it at large-scale quantities, 
however there was a great discover achieved by Eisai Company in Japan, which realized that 
simplified macrocyclic ketone analogs with approximately 70% of the molecular mass retained 
the activity of the natural product (NP) against tumor cells, allowing to identify the 
methanesulphonate salt of a terminal amino alcohol, eribulin mesylate, as the best candidate [5, 
6]. Eribulin mesylate was approved recently by FDA for breast cancer metastases [4]. 
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Brentuximab vedotin (SGN-35 or Adcetris® 5) is the most recent marine-derived drug approved by 
the FDA for treatment of Hodgkin’s lymphoma and melanoma [7, 8]. Brentuximab vedotin is an 
antibody-drug conjugate (ADC), composed by the chimeric anti-CD30 monoclonal antibody cAC10 
linked to the antimitotic agent monomethyl auristatin E (MMAE), via a valine-citrulline (vc) 
dipeptide linkage to the antibody (cAC10vc-MMAE). This ADC delivers and liberate free drug 
within the target cell by monoclonal-antibody interaction at the cell surface triggering the 
internalization, trafficking and release of the anticancer compound [9]. 
 
ET-743 or trabectedin (6), commercialized under the trade mark Yondelis®, is a MNP approved in 
the European Union isolated from the Caribbean tunicate Ecteinascidia turbinata, and is used for 
the treatment of soft tissue sarcoma. Due to the very low yield of isolation from the tunicate 
(around 10 parts per million), the methodology for the obtention of large-scale quantities 
involves both biotechnological processes and chemical synthesis, which starts with cyanosafracin 
B, an antibiotic that can be produced by fermentation of Pseudomonas fluorescens, and then 
followed by a 27 steps synthesis route to give the final product. The mechanism of action has 
been ascribed as to covalent modification of DNA by guanine-specific alkylation at the N2 position 
[5, 6, 10]. 
 
Soblidotin (TZT 1027, Auristatin PE 7) is a synthetic compound, inspired in the dolastatin family of 
compounds, specifically inspired in dolastatin 10, which due to toxicity problems in Phase II 
clinical trials was discontinued. TZT 1027 differs from dolastatin 10 in the replacement of the last 
amino acid residue, and has anticancer activity in several murine cancer models. This molecule 
shares the same mechanism of action as dolastatin 10, binding near the vinca peptide site on 
tubulin, inhibiting tubulin polymerization. Additionally, is a vascular disrupting agent (VDA), 
provocating the vasculature inside the tumor to collapse [5, 6]. 
 
GTS-21 [3-(2, 4-dimethoxybenzylidene)-anabaseine or DMXBA 8], is a synthetic compound 
derived from anabaseine, an alkaloid isolated from the marine worm Amphiporus lactifloreus 
(Phylum Nermetea). It is used to treat schizophrenia and Alzheimer´s disease, and selectively 
stimulates the α7 nicotinic acetylcholine receptors (α7 nAChR). Phase II clinical trials have 
revealed improvements in cognition function [5, 11]. 
 
Plinabulin (NPI-2358 9) is a completely synthetic compound inspired in the natural compound (-)-
phenylahistin (halimide), obtained from an Aspergillus specie derived from the Caribbean alga 
Halimeda lacrimosa. Plinabulin acts as an anticancer agent inhibiting tubulin polymerization and 
also as a VDA, inducing selective collapse of established tumor cells. The updated clinical trials 
have revealed improved therapeutic effects in combination with other anticancer agents [5, 10]. 
 
Plitidepsin (Aplidin® 10) is a very complex cyclic depsipeptide obtained from the Mediterranean 
tunicate Aplidium albicans. Is an extremely potent inducer of apoptosis at nanomolar levels and 
have not showed severe bone marrow toxicity. Phase II clinical assays are being carried out 
actually against pancreatic, colorectal and lung cancer [5, 6]. 
 
Elisidepsin (PM02734, Irvalec® 11) is an unnatural salt of the natural product isokahalalide F, 
which has been isolated from collections of the sea slug Elysia rufescens. Currently is undergoing 
through Phase II assays as antitumor agent against a variety of tumor cell lines [5, 10]. 
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PM00104 (Zalypsis ® 11) is an alkaloid related to jorumycin and renieramiycins, isolated from the 
Pacific nudibranch Joruna funebris and from several species of sponges, respectively. Is currently 
under Phase II clinical trials, as an apoptosis inducer by DNA-binding, giving rise to double-strand 
breaks. Showed preclinical in vivo potent activity against breast, prostate and renal cancer cell 
lines [5]. 
 
ILX-651 (Tasidotin or Synthadotin 13) is another synthetic analogue of dolastatin series of 
peptides, but in this case of dolastatin 15. It is a well-known tubulin disrupting agent, which is 
under Phase II assays, but has re-entered preclinical studies in order to improve routes and 
targets to enhance its efficacy [5]. 
 
The pseudopterosins are a 26 member class of glycosyl diterpenes isolated from the Caribbean 
soft coral Pseudopterogorgia elisabethae. Pseudopterosin A (PsA 14) is a powerful anti-
inflammatory and wound healing agent, which is currently in Phase II trials [5]. 
 
Bryostatin 1 (15) is a member of the total 20 different bryostatins coming from the bryozoan 
Bugula neritina. This intriguing compound have been in more than 80 anticancer clinical trials, 
and some of them are using this agent in combination with other chemotherapeutic drugs, such 
as Ara-C, paclitaxel, tamoxifen, aurastatin PE, dolastatin, vincristine, doxorubicin and prednisone. 
Currently there are also two Phase I clinical trials using it as anti-Alzheimer drug [5, 6, 10]. 
 
Hemiasterlin (E7974 16) is a total synthetic analogue of the natural hemiasterlin isolated from 
different marine sponges like Hemiasterella minor, which was designed based on extensive 
structure-activity relationships. E7974 is an antimitotic compound, via tubulin-based mechanism 
leading to tumor cell apoptosis. It´s clinical trials are currently under Phase I in patients with 
esophageal and prostate cancer [5, 6]. 
 
Marizomib (NPI-0052, Salinosporamide A 17) is a natural product isolated from the recently 
discovered marine bacterium Salinispora tropica, which possesses a novel β-lactone-γ-lactame 
moiety. Salinosporamide A displays a potent cytotoxic activity, and has initiated Phase I clinical 
trials in patients with multiple myeloma, lymphomas, leukemias and solid tumors. It exerts it´s 
action by selective inhibition of the proteasome that is an enzymatic complex responsible for the 
non-lysosomal protein degradation [4, 5]. 
 
The impact and success of marine invertebrate organisms as source of bioactive compounds is 
undeniable, but in recent years marine microorganisms have received and gained attention also 
as a promising source for drug discovery programs. This has been driven in part due to recent 
evidence that indicates that not always the “collected source” is the true “metabolic source”, i.e. 
that marine microorganisms are the responsible producers of the molecules, either by 
assimilation by an invertebrate grazer or growing in symbiotic association with an invertebrate 
host [12]. 
 
The marine microbial biodiversity is even greater than invertebrate biodiversity, and is believed 
to hold a vast number of species, of all bacteria, fungi and cyanobacteria. The most optimistic 
calculations state that around 0.01% to 0.1% of all marine microbes have been studied [4], which 
indicates the great potential still hidden in those organisms regarding their extraordinary 
biosynthetic features. This increasing interest of natural products chemists is clearly 
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demonstrated by the increasing number of compounds per year isolated from marine 
microorganisms, which for example for the period 2006-2007 presented an increment of 600% in 
comparison with the average of 1965-2005. It also can be seen an increment in comparison with 
other Phyla, for which the number of natural products discovered has remained practically 
constant [13]. Up to 2008 approximately 3000 compounds had been identified from marine 
microorganisms [4].  
 
There have been important advances in the use of microorganisms as source of therapeutic 
agents, since they are able to produce molecules with a wide range of bioactivities like 
anticancer, antimicrobial, anti-infective or immunosuppressant [4]. Their relevance is such great, 
that for example for the year 2008, of the 20 marine derived or inspired compounds which were 
in clinical trials for cancer, around 16 were of microbial origin [12], and for those in the current 
pipeline mentioned before, there are different types of evidence which reveals that 7 out of the 
17 compounds are produced by fungi, bacteria or cyanobacteria [14]. Microorganisms have also 
the advantage to provide larger quantities of compounds by large-scale fermentation procedures, 
compared for example with the cultivation of slower growing macroorganisms such as sponges 
[14]. 
 
1.3. Marine cyanobacteria 
 
1.3.1 A glimpse on cyanobacteria 
 
Cyanobacteria are among marine microorganisms on which many studies are actually being 
carried out. Cyanobacteria, traditionally known as “blue-green algae”, are an important group of 
Gram-negative photosynthetic prokaryotes of the Bacteria domain [15]. These microorganisms 
receive their name due to the presence of chlorophyll-a and phychocyanin, a blue-coloured 
phycobiliprotein (λmax 610-620 nm) that confers their characteristic blue color. However, some 
cyanobacteria species produce phycoerythrin (λmax 540-570 nm), a red phycobiliprotein, 
responsible of the red or brown color [16]. 
 
Cyanobacteria are considered the most ancient and successful life form present nowadays on 
Earth, since their fossil evidence that account for their presence, are dated back since more than 
3.5 billion years ago [17]. It is believed that cyanobacteria played a crucial role in the ecology and 
evolution of life forms in the planet, since they carried out the oxygenation process of primitive 
Earth´s atmosphere, leading to the appearance of more complex microorganisms and eukaryotic 
organisms too, in fact, there is evidence that indicates that the plastids of higher plants arise from 
a common ancestor, as a result of an endosymbiosis between a phagothrophic host and a 
cyanobacteria [15]. 
 
These prokaryotic photoautotrophs organisms are recognized for their ability to populate almost 
every conceivable habitat like soil, marine or freshwater environments, rocks (endolithic), plants 
or animals (endosymbionts), ice, as well as tolerate a variety of extreme conditions like 
temperature, pressure, salinity or pH [18-21]. 
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1.3.2 Morphological diversity and classification 
 
Morphologically the cyanobacteria may be classified in two big groups: filamentous and 
nonfilamentous forms. The nonfilamentous species are characterized to be spherical cells, or 
coccoid, which occur in unicellular or aggregate forms [15, 22]. Filamentous forms arrange in a 
row of cells, referred to as trichome, either with or without a sheat. In some filamentous species, 
can occur a true cell differentiation to form heterocysts, which unlike vegetative cells, are 
characterized by the absence of an oxygenic photosystem and are recognized as the responsible 
ones of nitrogen fixation [15]. Some heterocystous cyanobacteria may form a second type of 
cells, called akinetes which can germinate under suitable conditions as a survival strategy, due to 
their thick-wall structure [15]. All these morphological characteristics were the basis for the initial 
attempts for genus and species identification, when there were not genetic techniques for that 
purpose. Within the nonfilamentous there are two orders, Chroococcales and Pleurocapsales. 
Both of them are spherical cells in unicellular or aggregate forms held together by a gel-like 
matrix. Chroococcales reproduce by binary division in one, two or three planes or by budding, and 
may form symmetrical colonies or randomly distributed colonies of cells [22]. Pleurocapsales 
reproduce by multiple fission forming daughter cells smaller than the parent cells, or with 
multiple and binary fission. They also have the capacity to form motile cells [22]. 
 
The filamentous cyanobacteria are grouped in the orders: Oscillatoriales, Nostocales and 
Stigonematales. Oscillatoriales divide in one plane to form single filaments (trichomes), without 
heterocysts or akinetes [22]. Cyanobacteria of the order Nostocales also divide in one plane to 
form single filaments, but unlike Oscillatoriales, they form heterocysts when grown under low 
nitrogen concentrations. Some species may form akinetes too [22]. Cyanobacteria belonging to 
Stigonematales order, can divide in more than one plane, forming clumps of branched filaments 
on surfaces or in free water suspension [22]. 
 
This morphological approach for identification, however, has demonstrated to be not very 
accurate and appropriate, because some recent evidence, based on genetic analysis by 16S rRNA 
gene sequencing, clearly shows that taxa traditionally grouped by morphological similarities have 
really very distinct phylogenetic affiliations [23]. 
 
1.3.3 Harmful algal blooms (HABs) 
 
Cyanobacteria are among the species involved in the phenomenon known as Harmful Algal 
Blooms (HABs). The term Harmful Algal Blooms, have been designated, in the broad sense, 
traditionally to define the massive proliferation of a heterogeneous group of microorganisms, 
which are considered damaging by humans due to the adverse effects that may cause on human 
health, coastal zones where occur aquiculture and touristic activities, and in marine organisms 
populations. Although the term was initially applied to planktonic dinoflagellate´s blooms, 
nowadays its use has been expanded to any microalgal population, either planktonic or 
benthonic, even if cannot reach high cellular densities, but that may represent some risk [24], as 
is the case for the dinoflagellate Dinophysis which needs to be present only at hundreds of cells 
per liter to induce diarrhetic symptoms [25]. 
 
Massive proliferations of these organisms can colour the water, giving rise to red, green or brown 
tides, floating on the surface, or covering the beaches. These effects may cause the difficulty for 
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the establishment of aquatic macrophytes which will affect the underwater habitat for many 
animal species, due in part to, the nigh-time oxygen depletion. Additionally to this, HABs can also 
cause odour problems by the production of musty chemicals [25, 26]. Another mechanism by 
which certain species can exert their harmful effects is by the production of toxic compounds that 
can alter cellular processes of different organisms since plankton to animals. The most severe 
effects are on fish, birds and mammals including humans, in which may cause respiratory or 
digestive tract problems, seizures, memory loss, skin irritations and in some cases the dead [25]. 
 
Apart from cyanobacteria, toxic species involved in HABs are found in other groups such as 
raphidophytes, diatoms and dinoflagellates. According to the syndrome caused, toxins are 
classified into paralytic shellfish poisons (PSP), neurotoxic shellfish poisons (NSP), amnesic 
shellfish poisons (ASP), diarrhetic shellfish poisons (DSP), azaspiracid shellfish poisoning (AZP), 
ciguatera fish poisoning (CFP) and cyanobacteria toxin poisoning (CTP) [25]. 
 
Apart from the health and safety concerns, the interest in HABs include also adverse effects on 
living resources of many coastal systems, economic losses attributed to reduced tourism, 
recreation or seafood industries, and also for the costs required to maintain public advisory 
services and monitoring programs for shellfish toxins, water quality and plankton composition 
[25]. 
 
Although cyanobacterial Harmful Algal Blooms (CyanoHABs) have usually reported in freshwater 
bodies, in the last decades there have been an increasing number of reports of marine 
CyanoHABs, in tropical and subtropical areas all over the world. It has been established that the 
occurrence of these cyanobacterial blooms is directly related to increasing eutrophication and 
pollution processes, related in turn to anthropogenic activities such as urban, agriculture and 
industrial development [25-27]. These activities induce an over-enrichment of nutrients (mainly 
nitrogen and phosphorus) which favours the increasing of periodic HABs dominated by 
cyanobacteria in planktonic and benthic environments [26, 28]. But additionally to well-
established relations between nutrient enrichment and CyanoHABs, exist also evidence 
suggesting the role of diverse climate changes in the expansion of such blooms, particularly global 
warming [26, 28]. Warming, as with the other prokaryotes, can promote cyanobacterial growth, 
since their growing rates are optimized at relative higher temperatures compared to eukaryotes. 
This fact provides to cyanobacteria an advantage under nutrient-enriched conditions over 
eukaryotic primary producers like diatoms, chlorophytes, cryptophytes and dinoflagellates [26, 
28]. In addition to global warming, there are other environmental factors which can be implicated 
in cyanobacterial massive flourish, like carbon dioxide dynamics, rising salinities, changes in 
hydrology and the water shed, invasive species and grazer interactions [26, 28]. 
 
The phenomenon of CyanoHABs occurs seasonally and has been reported in several locations all 
around the world like for example in Japan, Australia, Hong Kong, Guam, United States [25], in 
certain Caribbean areas like Puerto Rico [29], Panama, Bahamas, Belize, Florida [30]. In South 
America there also have been reported cyanobacterial blooms in different countries like 
Argentina, Brazil, Chile, Uruguay, Paraguay, Peru, Venezuela, Surinam, and French Guyana [31]. In 
our country there are documented reports about CyanoHABs, but mainly related to aquiculture 
activities [32], and although there are reports about blooms of marine cyanobacteria in diverse 
locations of the Colombia Caribbean Sea, does not exist any formal register about these events. 
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1.3.4 Cyanotoxins 
 
The ecological role of cyanobacterial toxins, or cyanotoxins, is not very clear up to date and still 
remains under investigation. Toxicity to vertebrates may have occurred as a side effect during the 
evolution [33]. According to the mechanisms that toxins may exert, they are classified mainly into 
these groups: alkaloid neurotoxins, cyclic peptide hepatotoxins, cytotoxins, dermatotoxins and 
lipopolissacharides irritant toxins [33]. Marine bloom forming cyanobacteria are members of the 
Order Chroococcales and Oscillatoriales, mainly species of Synechocystis, Hormothamnion, 
Oscillatoria and Lyngbya [34]. The major toxin producer cyanobacteria are species and strains 
from common planktonic cyanobacterial general including Anabaena, Aphanizomenon, 
Cylindrospermopsis, Microcystis, Nodularia, Nostoc, Oscillatoria, Lyngbya, Scytonema and 
Tolypothrix [34]. 
 
 Neurotoxins 
 
Neurotoxins are produced by species and strains of Anabaena, Aphanizomenon, Oscillatoria and 
Trichodesmium [34]. These neurotoxins include the so-called group of anatoxins in which are the 
structurally close-related alkaloids anatoxin-a (18) and homoanatoxin-a (19) and the phosphate 
ester of a cyclic N-hydroxyguanidine, anatoxin-a(s) (20) [33]. Anatoxins affect the nervous system, 
the skin (swimmer´s itch) or the gastro internal tract [20]. Anatoxin-a isolated from Anabaena 
flos-aquae, Aphanizomenon flos-aquae and Oscillatoria sp., acts as a potent post-synaptic 
cholinergic nicotinic agonist, by irreversible binding to the nicotinic acetylcholine receptor of the 
sodium channel [33, 34]. Anatoxin-a(s) also isolated from Anabaena flos-aquae, blocks the 
acetylcholinesterase, so that after a signal transmission, acetylcholine is not removed from the 
nicotinic receptor by cleavage into its two component parts, acetic acid and choline [33]. 
 
Another important group of neurotoxins are the PSP toxins, which consist of more than 20 
members, all of them related derivates of a molecule consisting of tetrahydropurine group and 
two guanidinium moieties [33]. The major constituents of PSP are saxitoxin dihydrochloride (21) 
isolated from Aphanizomenon flos-aquae and Anabaena circinalis, and neosaxitoxin (22) [34]. 
These tricyclic alkaloids block neuronal transmission by binding to Na channels in nerve cells. The 
sodium gradient is thus stopped, which leads to muscle paralysis and subsequently to death in 
mammals [20]. 
 
Other types of neurotoxins are the lipopeptides kalkitoxin (23), and jamaicamides A, B and C (24-
26), isolated from several marine cyanobacteria species. These neurotoxins also block voltage-
gated sodium channels. Additionally, the non-protein amino acid L-beta-N-methylamino-L-alanine 
(27), produced by diverse cyanobacteria, may be associated with the development of the 
amyotrophic lateral sclerosis/Parkinsonism-dementia complex, a neurodegenerative disease [35]. 
 
 Hepatotoxins 
 
Hepatotoxins are the most common toxins found in cyanobacteria and include the cyclic peptides 
microcystins and nodularin. Microcystins (28-30)are cyclic heptapeptides isolated from species of 
Anabaena, Hapalasiphon, Microcystis, Nostoc and Oscillatoria [34]. To date, exist more than 80 
identified microcystins with different degrees of toxicity (i.p. mouse LD50 ranging from 50 to > 
1200 µg kg-1) [35], and all possess the general structure cyclo(-D-Alap1-Xaa2-D-MeAsp3-Yaa4-Adda5-
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D-Glu6-Mdha7-), where Xaa2 and Yaa4 are variable L-amino acids and define the suffix in the 
nomenclature, D-MeAsp3 is D-erythro-β-methyl aspartic acid, Mdha7 is N-methyldehydroalanine 
and Adda5 is the β-amino acid (2S,3S,8S,9S)-3-amino-9-methoxy-2,6,8-trimethyl-10-phenyldecy-
4(E),6(E)-dienoic acid [20, 35]. This amino acid was shown to be essential for the biological 
activity of microcystins via the covalent modification of proteins [20]. Microcystins are potent 
inhibitors of protein phosphatase-1 and -2A, which are essential for many signal transduction 
pathways of eukaryotic cells, such as apoptosis [20, 35]. It is believed that apart from their 
hepatotoxic activity, microcystins may have liver tumor promoter activity, since elevated levels of 
liver cancer have been reported in locations where presence of microcystins have been detected 
[20]. 
 
Nodularin (31) is a cyclic pentapeptide hepatotoxin that differs from microcystins by lacking the 
amino acids D-Alap1 and Xaa2 and by having L-Arg and N-methyldehydrobutyrine (Mdhb) instead 
of Yaa4 and Mdha7, respectively. Nodularin is produced by Nodularia spumigena and Nodularia 
harveyana, and like microcystins is also an inhibitor of phosphatase-1 and -2A and a potent tumor 
promoter [35]. 
 
Cylindrospermopsin (32), produced by Cylindrospermopsis raciborskii, Aphanizomenon 
ovalisporum, Aphanizomenon flos-aquae and others, is a potent cytotoxic alkaloid with a 
structure consisting of a tricyclic guanidinium moiety, combined with hydroxymethyluracil which 
has led to suppose that the mode of action of this compound is through DNA intercalation 
followed by strand cleavage [20, 35]. 
 
Table 1.2: Common cyanobacterial toxins. 
 
Cyanobacterial neurotoxins 
                           
                                                18. Anatoxin-a                                               19. Homoanatoxin-a                                               
                           
                                         20. Anatoxin-a                                         21. Saxitoxin dihydrochloride 
   
                                             22. neosaxitoxin                                                                   23. Kalkitoxin 
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24. Jamaicamide A R = Br; 25. Jamaicamide B R = H                                                    26. Jamaicamide C. 
 
27. L-beta-N-methylamino-L-alanine 
Cyanobacterial hepatotoxins 
 
28. X=Leu; Y=Ala Microcystin LA 
29. X=Tyr; Y=Ala Microcystin YA 
30. X=Leu; Y=Arg Microcystin LR 
 
                                                                31. Nodularin                                                                            32. Cylindrospermopsin 
 
1.3.5 Taxonomical origin of cyanobacterial bioactive compounds 
 
As mentioned before, cyanobacteria are capable to inhabit and adapt to a diversity of 
ecosystems, and in conjunction to the lack of physical defenses, have made cyanobacteria to 
develop a notorious arsenal of chemical defenses to preserve themselves from predators and 
ensure their survival. In that sense is believed that cyanobacterial toxins may have an ecological 
role of defense in which their diversity of secondary metabolites affect numerous targets involved 
in eukaryotic cell signalling processes [34]. Based on this point of view has been considered that 
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these compounds may have relevant biological properties to treat human diseases, and under 
this perspective, this have been the way in which extracts and pure compounds derived herein 
have been evaluated, resulting in their application in a very wide spectrum of bioactivities such as 
anti-viral, anti-bacterial, anti-fungal, anti-cancer, anti-leishmania, anti-malaria, 
immunosuppressive agents, anti-inflammatory, anti-HIV, cytotoxic, among others [20, 34, 36-38]. 
 
Until relatively recent time, the interest on marine cyanobacteria was focused by their known 
toxic effects, but built in part on the pioneering efforts of the late Professor Richard Moore since 
1970s through the early 2000s at the University of Hawaii [39], and the currently undergoing 
highlight discoveries by Professor William Gerwick at Scripps Institution of Oceanography of 
University of California San Diego [40], marine benthic filamentous cyanobacteria have revealed 
to be an extremely rich source of bioactive compounds with unusual structures and potent 
activities. 
 
Benthic filamentous marine cyanobacterial strains are the most common found in blooms, and 
these include taxa such as Lyngbya, Microcoleus, Phormidium, Schizothrix, and Symploca as well 
as the heterocyst-forming strains genera Rivularia and Scytonema [41]. For the approximately 800 
compounds isolated from marine cyanobacteria, have been these filamentous forms the most 
yielding species of natural products, with around 49% derived from cyanobacteria of the Order 
Oscillatoriales, followed by Nostocales with 26% and Chroococcales 15%, and finally the 
Pleurocapsales and Stigonematales Orders with 6% and 4% respectively (figure 1.2) [40, 41]. 
 
 
Figure 1.2: Percentage of cyanobacterial secondary metabolites by taxonomical order. Figure 
from reference 40.  
 
The genus from which have been isolated the greatest number of compounds is Lyngbya with 
more than 300, accounting for 35% of all cyanobacterial metabolites [41, 42]. Within this genus, 
the specie Lyngbya majuscula accounts for 76% of the compounds isolated with approximately 
240 metabolites. Lyngbya semiplena accounts for 5%, Lyngbya bouillonii for 3%, 14% are from 
undetermined Lyngbya species, and the remaining 2% from Lyngbya aestuarii, Lyngbya 
aerugineo-coerulea, Lyngbya confervoides and Lyngbya gracilis [42].  
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Other genera with significant number of metabolites isolated are Nostoc 11%, Oscillatoria 9%, 
Microcystis 7%, and Schizothrix 6%. And genera with smaller contributions are Anabaena 4%, 
Hapalosiphon 4%, Tolypothrix 4%, Symploca 3%, Phormidium 2%, Kyrtuthrix 2%, Scytonema 2% 
and Synechocystis 2%. The remaining 9 % comes from 23 different genera as can be seen in figure 
1.3 [42]. 
 
In the Microcystis genus (order Chroococcales) the specie M. aeruginosa accounts for 92% of the 
compounds isolated with a total of 49 compounds, 6% coming from M. viridis and 2% from 
undetermined species. [42]. 
 
From the genus Nostoc (order Nostocales) with a total of 73 compounds isolated, 91% of these 
have been obtained from unknown species. Nostoc commune accounts for only 6% of the isolated 
compounds, and Nostoc linckia, Nostoc muscorum and Nostoc spongiaeforme, each one with 1% 
[42].  
 
The genus Oscillatoria (order Oscillatoriales) with 64 compounds in total, has a broader 
distribution of isolated metabolites as compared to other genera. 30% comes from undetermined 
species, 28% from Oscillatoria agardhii, 19% from Oscillatoria nigroviridis and 13% from 
Oscillatoria spongelia. The species Oscillatoria raoi and Oscillatoria acutissima are responsible for 
3% each one and Oscillatoria rosea and Oscillatoria amphibian each one with a contribution of 2% 
[42]. 
 
 
Figure 1.3: Percentage of compounds isolated from marine cyanobacteria by genus. Figure from 
reference 42. 
 
Despite the cyanobacteria are wide spread distributed around the world, the majority of 
collections and chemical studies have been carried out in locations around the equator, mainly on 
the Caribbean, South Pacific and Indo-Pacific regions [43] in particular in Papua New Guinea, 
Guam and Palau [38] (figure 1.4). 
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Figure 1.4: Number of cyanobacterial collections by location based on publications from January 
2001 to December 2006. (PNG = Papua New Guinea). Figure from reference 38. 
 
1.3.6 Structural classes of marine cyanobacterial compounds 
 
Within the types of metabolites isolated from marine cyanobacteria, may be found fatty acid-
derived compounds, which in general lack recognizable amino acid components and also 
terpenes to a lesser extent. However the main metabolic theme found in cyanobacterial 
metabolites are the nitrogen-containing compounds called lipopeptides, which are the result of 
linking acetate and amino acids subunits, resulting in mixed polyketide (PK)-nonribosomal 
peptide (NRP) structural types, by means of the convergence of the polyketide synthase (PKS) and 
nonribosomal peptide synthase (NRPS) pathways [38, 41]. In fact, cyanobacterial lipopeptides 
come in two different categories: polyketide sections which transition into a nonribosomal 
peptide synthase section, thus forming amide or in some cases ester bonds (e.g., with α-hydroxy 
acids) which are described as “ketopeptides”, and the reverse sense where the carboxyl function 
of an amino acid serves as the starter unit for one or more polyketide extension, in which case 
are called “peptoketides”. Nevertheless, cyanobacterial natural products often possess elements 
of both of these two motifs, occurring as PKS-NRPS-PKS or NRPS-PKS-NRPS, in which case are 
called as “complex ketopeptides” or “complex peptoketides” [42]. 
 
The most abundant compounds are the ketopeptides which constitutes 251 compounds total, of 
these a considerable proportion are cyclic (60%), which is about the same for peptoketides. 
Halogenation occurs in the same proportion of 36% such for ketopeptides and for regular 
polyketides, but for peptoketides is much lower (8%). For polyketides, around 10% are 
glycosylated while one-third of them are halogenated [42]. Of pure peptide secondary 
metabolites isolated from cyanobacteria, approximately 70% are cyclic and only 9% are 
halogenated. Both, terpenes and alkaloids are not very abundant in cyanobacteria (52 and 66 
compounds respectively), but also show interesting structural features. For example terpenes, 
either pure or in combination with other biosynthetic components, occur primarily as fused 
polycyclic structures (> 50% for both classes), and often tend to be glycosilated. Alkaloids in turn, 
show a high degree of halogenations (47%) and approximately 23% are glycosilated. All these 
features of cyanobacterial compounds are summarized in figure 1.5 [42]. 
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Figure 1.5: Structural characterization of marine cyanobacterial natural products. Figure from 
reference 42. 
 
1.3.7 Metabolic building blocks 
 
As mentioned above, the majority of the bioactive cyanobacterial compounds are polyketides, 
nonribosomal peptides or hybrid polyketide-nonribosomal peptides. These are molecules build by 
acetate or propionate units as well as proteinogenic and non-proteinogenic amino acids, all of 
them which have the particularity, and on this is based their relevance and interest, that these 
building blocks present different types of modifications leading in the great structural diversity 
found in secondary metabolites from marine cyanobacteria. Acetate-derived units can be used in 
several ways to synthesize these hybrid compounds. First, the acetate units can be coupled 
through amide bonds with several functionalized amines. The fatty acid chain obtained from the 
acetate units can undergo through several common modifications such as methylation and 
halogenation. Single or multiple acetate units can be used for the extension of some amino acids, 
such as alanine, phenylalanine, proline and glycine. This extension can be linear or go through 
cyclization to form common moieties like pyrrolonone rings [38]. 
 
Non-proteinogenic amino acids are originated from polyketide-derived units occurring as β-
hydroxy of β-amino acids, and the molecules with these particular subunits have the property to 
exhibit potent bioactivities, inherent due to their stability and resistance to proteolysis. The 
length of the fatty acid chain can range from 4 carbons to 12 carbons, and are usually 
characterized for the occurrence of methylation or dimethylation at the α-carbon position, as well 
as alkene or alkyne functional groups at the terminal end. Other modifications along the carbon 
chain like hydroxylation and dichlorination can take place [38]. A unique characteristic of marine 
cyanobacterial compounds is the use of unusual starter units in polyketide extension, like the 
proposed 2,2-dimethyl-propionic acid. Although there is evidence that most of the pendant 
methyl groups derive from either S-adenosyl methionine or from C2 of acetate [43]. 
 
The most usual proteinogenic amino acids used in the biosynthesis of marine cyanobacterial 
peptides are mainly neutral, for example, valine, alanine, phenylalanine, isoleucine, proline, 
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cysteine, serine, leucine and glycine. All these amino acids may undergo through several 
modifications like N- and O-methylation. It is also common to find α-hydroxy acids residues as 
lactic acid, α-hydroxy isoleucic acid and phenyllactic acid. And as a particular characteristic of the 
cyanobacterial compounds, other amino acid modifications can occur like hydroxylation, homo 
variants (i.e., extension of the lateral chain of the amino acid in one carbon), dehydrated amino 
acids and halogenated derivates. It is also common modified amino acid residues like cysteine, 
serine and threonine, which can undergo through cyclization to give the thiazole and oxazole 
heterocyclic rings with different oxidation states varying from their totally reduced equivalent to 
the aromatic forms of these [38]. 
 
In figure 1.6 can be seen the distribution of the occurrence of amino acids in marine 
cyanobacterial metabolites, and be noted that of the total, the aliphatic residues (Ala, Val, Leu, 
Ile, Pro, Phe) are around 70% being Val the most commonly occurring amino acid with 273 
occurrences followed by Tyr with 215, Ala with 190, Pro with 187, Thr with 186, Ile with 173, Leu 
with 158, Phe with 141 and Gly with 126 occurrences. The polar non-charged residues (Gly, Cys, 
Tyr and Ser) are the second class of amino acids of major utilization. And is also remarkable that 
unlike the peptide natural products of freshwater cyanobacteria, the basic (Lys, Arg and His) and 
the acidic amino acid residues (Asp, Glu) are absent [42, 43]. 
 
 
Figure 1.6: Number of occurrence of amino acids in cyanobacterial natural products. Figure from 
reference 42. 
 
When taken into account the type of modification of amino acids found in cyanobacterial 
metabolites, as can be seen in figure 1.7, around 49% of the times they are incorporated into the 
peptides without any modification, but when modified incorporation takes place, they are most 
commonly altered by N-methylation (17%) or N,N-dimethylation (3%), incorporation into a 
heterocyclic ring (13%), polyketide extension (6%), hydroxylation, usually at β position (4%), and 
O-methylation (2%). The most common amino acid found with N,N-dimethylation is valine, as it 
forms the N-terminus of many bioactive peptoketides, but is most commonly found without any 
modification or N-methylated. Tyrosine is one of the amino acids that shows more modifications, 
including N-methylation, O-methylation, N,O-methylation and halogenation. Gly and Ile show the 
highest prevalence of polyketide extension, followed by Ala, Val and Pro. As mentioned before, 
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Cys and Thr are involved in the formation of the 5-membered heterocyclic rings with the carbonyl 
of adjacent amino acids, which usually are Ala, Val, Phe or Ile, and is interesting to observe that 
threonine tends to form oxazoline rings retaining the original stereocenter of the amino acid, but 
cysteine (which never occurs as an unmodified amino acid) tends to form thiazole rings, leading 
to losing its chiral center [42]. 
 
About the stereochemistry of the amino acids used in marine cyanobacterial metabolites, it is 
found that they are predominately incorporated into the L- form, either if they are modified or 
not, but sometimes they can undergo epimerization as the D-form (figures 1.8 and 1.9) [42].-β-
amino acids are also broadly prevalent in marine cyanobacterial metabolites. A majority of these 
possess an α-methyl group. A number of unique halogen modifications also occur within 
cyanobacterial compounds. These include the trichloromethyl, vinyl chloro, gem-dichloro, 
aromatic chloro, aromatic bromo, alkyne bromo and the aromatic iodo groups, which reveal the 
extraordinary metabolic machinery that marine cyanobacteria have to carry out the covalent 
incorporation of halogens into their secondary metabolites [43]. 
 
Both unique characteristics of marine cyanobacteria, the great structural diversity of their 
secondary metabolites and the application to a wide range of bioactivities demonstrates their 
relevance and for that reason there is an increasing interest to understand how these unusual 
compounds are synthesized, focusing mainly on mechanistic biochemistry, gene evolution, 
transcriptional regulation and biosynthetic logic. All the advances made in the molecular biology 
of cyanobacterial natural products have been made possible thanks to the enormous advances in 
genome sequencing technology, identifying genomes with the capability of natural products 
biosynthesis, and also to better understand the mechanisms of unusual transformations present 
in marine cyanobacterial compounds, such as halogenation, reduction, cyclization, methylations, 
unusual chain terminations, decarboxylation, etc [44]. All these efforts in understanding the 
biosynthetic machinery, genome mining and gene sequencing are aimed to access to the full 
richness of cyanobacterial natural products, as well as to employ the genes in heterologous 
expression and combinatorial biosynthesis, and also to solve the supply problem 
pharmacologically relevant compounds, which are obtained in very low amounts [45, 46]. 
 
 
Figure 1.7: Occurrence of modifications of amino acids typically found in marine cyanobacterial 
natural products. Figure from reference 42. 
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Figure 1.8: Chirality of unmodified amino acids incorporated into marine cyanobacterial natural 
products. Figure from reference 42. 
 
Figure 1.9: Chirality of N-methylated amino acids incorporated into marine cyanobacterial natural 
products. Figure from reference 42. 
 
With all the previous background showed, is evident the ecological and biotechnological 
importance of marine cyanobacteria, which constitutes a state-of-the-art topic in marine natural 
products investigation with promising results and great potential. So, this chapter pretends to lay 
the background of the research in this novel area for the very first time in Colombia, by evaluating 
the toxic effects of some species involved in cyanobacterial blooms in San Andres and Old 
Providence Islands, and making a first approach to their bioactivity evaluation in different assays, 
and isolating and identifying non-ribosomal peptides from these microorganisms. For this 
purpose, was performed Artemia salina lethality assay to evaluate and establish the toxicity of 
the cyanobacteria collected, and evaluate their potential and biological application by means of 
the antileishmania and cytotoxicity against several cancer cell lines. And finally from the most 
toxic sample carry out isolation and elucidation of the secondary metabolites obtained, and the 
evaluation of their biological activity in one the bioassays previously described. 
 
  
 
Chapter 2  
2 Evaluation of biological activity of marine 
cyanobacteria extracts collected at San Andres and 
Old Providence Islands 
 
2.1. Introduction 
 
The first report on cyanobacterial toxins dates back to 1878 in a farm in Australia, when the 
specie Nodularia spumigena formed a thick scum-like green oil paint on the surface of the Murray 
River, and caused death on animals, particularly livestock, that drank on these water bodies [47]. 
Since then, there have been reports on cyanobacterial toxins and on their ecological and 
economical impact. 
 
Freshwater cyanobacteria have been traditionally known and studied for their impact and risks 
that represent, and for that reason are particularly well documented [48, 49]. However, studies 
on marine cyanobacterial HABs have not been performed to the same extent and those are 
mainly from tropical regions where the occurrence of those events has been reported [50, 51]. 
During the last decades there has been an increase in the number of Marine CyanoHABs cases 
reported. While several decades ago just a few locations were affected by these CyanoHABs, 
nowadays more coastal countries all around the world are being affected by this problem, as 
demonstrated in figure 2.1 where shows the global distribution, for example of PSP toxins in 1970 
compared to 2006 [52]. Marine CyanoHABs are associated with eutrophication of coastal water, 
caused by anthropogenic activities such as sewage runoff, agriculture runoff and discharge of 
industrial wastes [29, 53]. Benthic cyanobacteria are rare in healthy coral reefs, they use to occur 
on damaged surfaces and sick corals, but prefer to form loose mats and colonies over sandy 
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sediments or epiphytically on sea grass. Their continuing growing is contingent on competition 
with eukaryotic algae and sedentary animals [27]. 
 
 
Figure 2.1: Comparison of global distribution of PSP toxins in 1970 and 2006. Figure from 
reference 52. 
 
As marine CyanoHABs when dominated by toxic species are a serious concern for public health, 
human activities and animal life, the evaluation of their toxicity is crucial to establish their 
potential impact. So, for the evaluation of cyanobacterial toxicity the brine shrimp Artemia salina 
assay has been employed in several cases as a valid preliminary method [54, 55] and is used for 
cyanotoxin detection in coastal environments [56]. 
 
2.2. Bioactive natural products from marine cyanobacteria 
 
Besides from the “typical” view of cyanobacteria as an environmental nuisance or producers of 
toxins harmful to man, these prolific microorganisms have proved to be useful in the discovery of 
new pharmacologically relevant compounds. They have been source of compounds with anti-
bacterial, anti-viral, anti-fungal and cytotoxic activities [38, 57, 58]. 
 
2.2.1. Marine cyanobacterial secondary metabolites as promising 
anticancer agents 
 
Cyanobacteria have highlighted to be a prolific source of anticancer compounds [41, 59], 
estimating that around 35% of the 20 marine-derived anticancer agents in clinical trials could 
have marine cyanobacteria as the biogenic source [60]. One of the most observed characteristics 
of these cyanobacterial anticancer compounds is their preference to act as antimitotics 
Chapter 2 27
 
 
interfering with microtubules of actin filaments. However, they have a remarkable versatility to 
exert their action through a variety of mechanisms such as histone deacetylase (HDAC) inhibitors, 
serine protease inhibitors and modulators of cell death and apoptosis, apart from some other 
compounds with unknown specific pharmacological targets [41]. 
 
 Microtubule disruptors 
 
Because of microtubules and actin filaments are involved in mitosis, cell motility and signalling 
processes, compounds that target these crucial constituents of the cytoskeletons are important 
as anticancer agents. 
 
- Dolastatins 10/15 and analogues 
 
In the current pipeline of marine derived drugs, there are two anticancer agents called Soblidotin 
(33) and Synthadotin (34). These two compounds that showed potent microtubule disruption 
activity were derived from two initial cyanobacterial compounds, dolastatins 10 (35) and 15 (36), 
respectively. The discovery of dolastatin family of compounds, started in 1972 during an 
expedition to Western Indian Ocean, and were originally reported from the sea hare Dolabella 
auricularia [6]. Due to the very low yields of dolastatins isolated from the invertebrate, they were 
initially speculated to be derived from its diet, and subsequent isolation of a series of dolastatins 
from marine cyanobacteria, from which D. auricularia feeds on, confirmed is microbial origin [61]. 
 
Dolastatin 10 is a linear depsipeptide containing four non-proteinogenic amino acids: N,N-
dimethylvaline, dolaisoleucine, dolaproline and dolaphenine. Among the dolastatins, is the most 
potent cancer cell growth inhibitor. The GI50 values of dolastatin 10 against several tumor cell 
lines including OVCAR-3, SF-295, A498, NCI-H460, KM20L2 and SK-MEL-5 were 9.5×10-7, 7.6×10-6, 
2.6×10-5, 3.4×10-6, 4.7×10-6 and 7.4×10-6 µg.mL-1, respectively [41]. Its mechanism of action is by 
binding on tubulin at a distinct site near to the Vinca alkaloid site, which causes cells to be 
arrested in the metaphase [6, 41]. One of the reasons for the high antimitotic activity is its 
prolonged intracellular retention that facilitates binding to tubulin [6]. In 1990s, dolastatin 10 
entered clinical trials at National Cancer Institute and progressed to Phase II assays against 
prostate adenocarcinoma, NSCLC, melanoma, colorectal cancer, soft-tissue sarcomas, breast 
cancer and pancreaticobiliary cancers [6]. However, its not very good results as anticancer agent 
additionally to the development of peripherial neuropathy in 40% of patients, did not justify 
continue evaluating dolastatin 10 in clinical trials [41]. Nevertheless, structure-activity 
relationships (SAR) studies resulted in the development of the synthetic analog TZT 1027 or 
Soblidotin, with reduced toxicity and improved pharmacological properties, and is currently 
undergoing Phase III clinical trials. The mechanism of action is the same as dolastatin 10, but 
additionally is also a vascular disrupting agent (VDA), causing the vasculature inside the tumor to 
collapse [5]. TZT 1027 differs from dolastatin 10 in replacement of the terminal dolaphenine 
amino acid residue with a simple phenethylamine group [6]. 
 
Apart from dolastatin 10, dolastatin 15 is another potent antimitotic agent, that although has not 
been re-isolated from a marine cyanobacterium, due to its invertebrate primary origin and to a 
number of cyanobacteria-derived dolastatin 15 analogues reported, is believed also to be 
synthesized by cyanobacteria. Dolastatin 15 is a peptide consisting of seven amino or hydroxyl 
acid units, and shares the same mechanism of dolastatin 10. It did not enter clinical trials, but a 
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third generation simplified synthetic analog (ILX-651 or Synthadotin) was developed, and with 
improved stability and bioavailability. Synthadotin is under Phase II clinical trials on patients with 
hormone refractory prostate cancer and advanced or metastatic non-small-cell-lung carcinoma 
[41]. 
 
- Curacin A 
 
Curacin A (37) is the most potent member of the curacin class of cyanobacterial lipopeptides, 
characterized for having a thiazoline moiety. It was isolated from a Lyngbya majuscula sample 
from Curaçao as the major component (8-10%) [62]. This compound was subjected to the NCI 60 
cell line screening, and revealed to be a potent anti-tubulin drug with IC50 value of 0.72 µM. 
Curacin A, specifically binds to the colchicine site of tubulin, and when colchicine binding was 
tested at 5 µM, was about 94%, demonstrating its high potency, and in addition to its unusual 
structural characteristics, many synthetic efforts were carried out to complete its total synthesis, 
and numerous synthetic analogues were also obtained by SAR studies. The most promising 
analogue was 38, which is three times more potent than curacin A, inhibiting polymerization of 
tubulin with a IC50 value at 0.17 µM [41]. Also, in order to resolve the supply problem for this 
compound, the culture of curacin-producing L. majuscula strains was evaluated [63]. 
 
 Actin disruptors 
 
- Lyngbyabellins/hectochlorin 
 
These are unique bithiazole-containing type of compounds, which possess the unusual amino acid 
residue 7,7-dichlro-3-hydroxy-2-methyl-octanoic acid. Hectochlorin (39), isolated from L. 
majuscula collected in Jamaica showed in the NCI 60 cancer cell lines, significant cytotoxicity 
against melanoma, ovarian and renal cells. Hectochlorin is a potent stimulator of actin 
polymerization in PtK2 cells with an EC50 value at 20 µM [41]. 
 
The hectochlorin-related compounds lyngbyabellins A (40) and E (41), from Guam and Papua New 
Guinea collections of L. majuscula respectively, displayed moderate cytotoxicity against various 
cell lines, at concentrations of 0.01-5.0 µg.mL-1. However, in vivo assays showed to be lethal to 
mice when injected at 2.4 to 8.0 mkg.kg-1 [41]. 
 
- Dolastatin 11 and analogues 
 
Dolastatins 11 (42) and 12 (43) are highly potent cytotoxic cyclic depsipeptides, isolated also from 
the sea hare D. auricularia. These molecules are constructed by eight amino acids and one 
hydroxyl acid residues, and belong to the “ketopeptide” structural class of compounds. Some of 
the isolated derivates from several cyanobacterial species include majusculamide C (44), 
lyngbyastatins 1 (45) and 3 (46). When tested against different cell lines, like NCI-H460, OVCAR-3, 
SF-295 and KM20L2, dolastatin 11 showed GI50 values in the nanomolar range. Its activity is due 
to disruption of microfilaments by hyperpolymerization of actin, leading to cytokinesis inhibition. 
Despite its promising activity, dolastatin 11, has not continue to clinical assays, due to reports of 
other analogues displaying toxic effects such as pulmonary hemorrhage in mice [41]. 
Desmethoxymajusculamide C (47) from a Fijian collection of L. majuscula was found to be highly 
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cytotoxic in both cyclic and ring-opened forms, at 52 nM against A-10 cells inducing the loss of 
filamentous F-actin [41]. 
 
 Histone deacetylases (HDAC) inhibitors 
 
- Largazole 
 
Largazole (48) is a 16-membered depsipeptide isolated from the Florida Key cyanobacterium 
Symploca sp. It has a number of unique structural characteristics like the presence of 4-
methylthiazoline linked to a thiazole unit, and a 3-hydroxy-7-mercaptohept-4-enoic acid unit, 
added to the presence of a thioester functional group never reported before in marine 
cyanobacterial compounds [41]. Largazole exhibits an extraordinary nanomolar activity against 
transformed human mammary epithelial cells (MDA-MB-231) with GI50 at 7.7 nM and against 
transformed fibroblastic osteosarcoma cells (U2Os) at GI50 of 55 nM [41, 57]. This compound is a 
potent class I HDACs inhibitor, which are overexpressed enzymes in colon and prostate tumors, 
which become an important pharmacological target in chemotherapy. SAR studies have made 
possible to conclude that the (S)-3-hydroxy-7-mercaptohept-4-noic acid moiety is crucial for the 
activity of largazole and its derivates such as 49-51 [41]. 
 
 Serine protease inhibitors 
 
- Lyngbyastatins 
 
Serine proteases are a class of proteolytic enzymes like elastase, chymotrypsin and trypsin, and 
are found in eukaryotic and prokaryotic cells. These classes of enzymes are involved and crucial in 
various diseases states like emphysema, gingivitis, inflammatory infections and the destruction of 
extracellular matrix of articular cartilage and bone in arthritic joints, and have also been 
demonstrated that inhibition of proteases would represent a new pharmacological target for 
treatment of cancer. One of the first serine protease inhibitors compounds from marine 
cyanobacteria are lyngbyastatins 4 (52) and 7 (53) from a Floridian collection of Lyngbya sp. These 
were evaluated against elastase, and chymotrypsin enzymes with IC50 values at 0.03 and 0.30 µM 
for lyngbyastatin 4, and 0.0083 and 2.5 µM for lyngbyastatin 7, and both were not active against 
trypsin at 10 µM. Somamide B (54) isolated from two different collections of Lyngbya sp. from Fiji 
and Florida also inhibited potently elastase. Symplocamide A (55) was found to be selective 
against chymotrypsin with an IC50 of 0.38 µM, and is also active against NCI-H460 non-small lung 
cells and neuroblastoma cells with IC50 values at 40 and 29 nM, respectively. Other serine 
protease inhibitors from marine cyanobacteria include kempopeptins A (56) and B (57), 
pompanopeptin A (58) and largamides D-G (59-62). All these serine protease inhibitor compounds 
share the structural moiety 3-amino-6-hydroxypiperidone (Ahp), which seems to be the 
pharmacophore of these molecules [41]. 
 
 Apoptosis inducers 
 
- Somocystinamide A 
 
Isolated from a mixed cyanobacterial assemblage of L. majuscula and Schizothrix sp. from Fiji, this 
disulfide dimer (63), containing two distinctive N-methyl enamide groups, showed a potent 
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apoptosis inducer activity in the nanomolar range, in cancer cell lines. It has been proposed that 
somocystinamide A functions through activation of the death-inducing signaling complex in cell 
membranes by activation of caspases 8 and 3, which constitutes an interesting target for tumor 
suppression. Additionally was observed anti-angiogenetic effects on zebra fish model [41, 57]. 
 
- Apratoxins 
 
The apratoxins have been isolated from several collections of Lyngbya sp. from Guam, Palau and 
Papua New Guinea. Apratoxin molecules consist of a tetrapeptide chain, a thiazole unit and a 
polyketide chain as part of the cyclic carbon skeleton. These cyclic depsipeptides have exhibited 
potent in vitro cytotoxicity in various tumor cell lines with IC50 values ranging from 0.36 nM in 
LoVo cells to 0.52 nM in KB cells. A total of 7 apratoxins A-G (64-70) have been isolated, and they 
show a number of modifications, including absence of an N- or C- methyl group at various 
positions, an additional PKS module early in the biosynthetic sequence, or replacement of a 
terminating proline residue with an N-methyl alanine. Studies about their mechanism of action 
have revealed that apratoxins may have a multitude of effects on the cells, including targeting of 
Heat Shock Protein (HSP) 90 that plays an important role as positive regulator of cell proliferation 
in cancer cells [41, 57]. 
 
 Other potent anticancer compounds from marine cyanobacteria 
 
- Aurilides and analogues 
 
The first molecule, aurilide (71), was first isolated from the Japanese sea hare D. auricularia, but 
later other analogues like aurilides B (72) and C (73) were isolated from a L. majuscula collection 
from Papua New Guinea. The aurilides are 26-membered cyclic depsipeptides comprised of six 
amino acids and a polyketide derived fragment. Aurilides B and C showed highly in vitro 
cytotoxicity against NCI-H460 and the neuro-2a mouse neuroblastoma cell lines with LC50 values 
at 40 and 10 nm, and 130 and 50 nM, respectively. Further, aurilide B was evaluated in the NCI 60 
cell line panel and displayed potent activity against various cancer cell lines such as leukemia, 
renal and prostate with average GI50 <10 nM. A structurally related compound, palau´amide, 
obtained from a Palauan strain of Lyngbya sp., was very active against KB cells with an IC50 value 
of 13 nM, but the continuation of biological tests was not possible due to lack of natural sample 
[41]. 
 
- Kulokekahilide-2 
 
A compound isolated initially from the Hawaiian marine mollusk Philinipsis speciosa, called 
kulokekahilide-2 (74), was very active against cell lines such as P388, SK-OV3, MDA-MB-435 and 
A-10, with IC50 values ranging from 4.2 to 59.1 nM. It has been proposed that kulokekahilide-2 is 
biosynthesized by marine cyanobacteria because its narrow structural similarity with aurilides 
[41]. 
 
- Coibamide A 
 
Isolated from the Panamanian marine cyanobacterium Leptolyngbya sp., this compound has a 
very intriguing structure with no PK moieties, a high degree of N-methylation where eight out of 
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11 residues are N-methylated, and is composed of a large macrocyclic ring as well as a linear 
peptide section. Coibamide A (75) showed high cytotoxicity to NCI-H460 lung cancer cells and 
neuro-2a cells with LC50 of <23 nM. Additionally to this, the evaluation in the NCI´s in vitro panel 
of 60 cancer cell lines, showed high activities against MDA-MB-231, LOX IMVI, HL-60(TB) and SNB-
75 at 2.8, 7.4, 7.4 and 7.6 nM, respectively, no interfering with tubulin or actin filaments, but 
acting as an anti-proliferative agent through a novel mechanism [41, 57, 64]. 
 
- Bisebromoamide 
 
Bisebromoamide (76) is a cytotoxic linear peptide isolated from an Okinawan strain of Lyngbya 
sp., that possess activity against 39 cancer cell lines with an average IC50 of 40 nM. Its structure is 
very particular as is highly functionalized, because six of the eight amino acids contain unusual 
modifications, such as N-methyl-3-bromo-tyrosine, a modified 4-methylproline, a 2-(1-oxo-
propyl)pyrrolidine, and a N-pivalamide [41, 57]. 
 
- Hormothamnin A and laxaphycins 
 
Hormothamnin A (77) was obtained from the Puerto Rican marine cyanobacterium 
Hormothamnnion enteromorphoides, and the laxaphicins were isolated from the French 
Polynesian marine cyanobacterium L. majuscula but previously reported from the fresh water 
cyanobacterium Anabaena laxa. Hormothamnin A and laxaphycin A (78) are very close-related 
compounds differing only in the configuration of the Dhb residue, but this minor structural 
difference is enough for both compounds to display quite different bioactivities, making the 
former molecule to be more cytotoxic with IC50 values ranging from 0.13 to 0.72 µg.mL
-1 against a 
variety of solid cancer cell lines, like SW1271 (human lung), A529 (human lung), B16-F10 (murine 
melanoma) and HCT-116 (human colon). Among laxaphycins, laxaphycin A is less active than 
laxaphycin B (79) when tested against non-small-cell lung (A549), MCF7 (breast), ovary (PA1), 
prostate (PC3) and colon (DLD1) cancer cell lines. The cytotoxic activity of laxaphycin B was 
significantly increased when tested in conjunction with laxaphycin A, and it has been suggested 
that the mechanism of action of laxaphycin B is different when tested alone than when 
administered together with laxaphycin A [41]. 
 
Table 2.1: Potent and promising anticancer compounds isolated from marine cyanobacteria 
 
Microtubule disruptors 
 
          
                                33. Soblidotin                                                                                                     34. Synthadotin 
 
        
                                35. Dolastatin 10                                                                               36. Dolastatin 15 
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                                   37. Curacin A                                                                                                38            
Actin disruptors 
          
                                                             39. Hectochlorin                                                                   40. lyngbyabellin A 
 
                                                                                                            41. lyngbyabellin B 
 
Histone deacetylases (HDAC) inhibitors 
                                
 
 
48. Largazole 2S, 17S, R=n-C7H15CO 
49. 2R, 17S, R=n-C7H15CO 
50. 2S, 17R, R=n-C7H15CO 
51. 2S, 17R, R=H 
42. Dolastatin 11 R1=H; R2=OCH3; R3=H; R4=CH3; R5=CH3; R6=CH2CH3 
43. Dolastatin 12 R1=CH3; R2=H; R3=H; R4=CH3; R5=CH3; R6=CH2CH3 
44. Majusculamide C R1=H; R2=OCH3; R3=CH3; R4=H; R5=CH3; R6=CH2CH3 
45. Lyngbyastatin 1 R1=CH3; R2=OCH3; R3=H; R4=CH3; R5=CH3; R6=CH2CH3 
46. Lyngbyastatins 3 R1=CH3; R2=OCH3; R3=H; R4=H; R5=CH3; R6=CH2CH3 
47. Desmethoxymajusculamide C R1=H; R2=H; R3=CH3; R4=H; R5=CH3; 
R6=CH2CH3 
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Serine protease inhibitors 
 
   
                                 52. Lyngbyastatin 4                                                                                      53. Lyngbyastatin 7  R=(CH2)4CH3 
                                                                                                                                                                                                                                                     54. Somamide B        R=(CH2)2CH3 
 
      
                                55. Symplocamide A                                                                                      56. kempopeptin A 
 
 
                            57. Kempopeptin B                                                                          58. Pompanopeptin A 
 
 
 
 
 
59. X=Br; R= L-Leu 
60. X=Cl; R= L-Leu 
61. X=Br; R=  L-Tyr 
62. X=Br; R=  L-hTyr 
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Apoptosis inducers 
      
                      63. Somocystinamide A 
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                                67. Apratoxin D                                           68. Apratoxin E                               69. Apratoxin F; 70. Apratoxin G                                                       
 
Other potent anticancer compounds from marine cyanobacteria 
        
 
                                                                                                                  74. Kulokekahilide-2 
 
 
 
75. Coibamide A 
64. Apratoxin A R1; R2=CH3 
65. Apratoxin B R1=H; R2=CH3 
66. Apratoxin C R1=CH3; R2=H 
71. Aurilide R1=CH3; R2=H (D-MeLeu) 
72. Aurilide B R1=CH3; R2=CH3 (allo-L-MeIle) 
73. Aurilide C R1=H; R2=CH3 (allo-L-MeIle) 
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76. Bisebromoamide 
 
                                               77. Hormothamnin A                                                                         78. Laxaphycin A 
 
 
        79. Laxaphycin B 
 
2.2.2. Pharmacologically neuroactive compounds from marine 
cyanobacteria 
 
All the previous revision has pointed out the undeniable importance of filamentous marine 
cyanobacteria as source for anticancer agents, showing some of the most promising and potent 
compounds. Nevertheless, an emerging interest on marine cyanobacterial has been appearing for 
their use in other therapeutic areas. For instance, a considerable number of 
neuropharmacological agents have been recently reported, which appear to target the Voltage 
Gated Sodium Channels (VGSC) as blockers or activators. The neurotoxic properties of these 
molecules are quite exciting, since their activity in the nanomolar range. These cyanotoxins are 
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source of valuable tools in functional characterization of VGSC, as well as being potential 
analgesics and neuroprotectants [38]. 
 
Notable among these compounds are hoiamides A (80) and B (81), palmyrolide A (82) and 
alotamide A (83). Hoiamides are a class of cyanobacterial compounds isolated from several mixed 
collections of Symploca and Oscillatoria from Papua New Guinea. Hoiamides are mixed PK-NRP 
compounds, characterized by an unusual 15-carbon long linear polyketide chain, a tri-heterocyclic 
ring system composed of two α-methyl thiazolines and one thiazole, a PKS extended isoleucine 
residue, and a number of additional amino- or hydroxyl-acids [57]. Hoiamides A and B isolated by 
a bioassay-guided procedure using sodium channel activating activity in neuro-2a cells, have 
revealed to stimulate sodium influx with EC50 values of 1.7 and 3.9 µM, respectively [65, 66]. 
 
A Palmyra collection of marine cyanobacterial strains of Leptolyngbya sf. and Oscillatoria spp. was 
found to have potent modulator of sodium channel activity. It was found the active compound, 
named palmyrolide A, to be a cyclic lipopeptides with eneamide and lactone connections, and 
which in pharmacological exhibited Ca2+ oscillations inhibition in murine cerebrocortical neurons 
with an IC50 of 3.7 µM, and block of VGSCs in neuro-2a cell with an IC50 of 5.2 µM, with no 
cytotoxicity up to 20 µM [57, 67]. 
 
Alotamide A, was isolated from a Lyngbya bouillonii strain collected in Papua New Guinea. Its 
structure consists of three contiguous amino acid residues and an unsaturated heptaketide 
moiety. This compound showed an unusual calcium influx activation profile in murine 
cerebrocortical neurons with an EC50 of 4.18 µM through an undetermined mechanism of action 
[68]. 
 
Table 2.2: Pharmacologically neuroactive compounds from marine cyanobacteria. 
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2.2.3. Marine cyanobacterial compounds as anti-infective agents 
 
Recently, the International Cooperative Biodiversity Group (ICBG) of Panama has been working 
extensively on marine cyanobacteria for their anti-parasitic activities for the treatment of 
diseases such as malaria, leishmania and Chagas disease [57]. As remarkable examples of 
compounds isolated with these biological activities are, calothrixins A (84) and B (85) [69], 
venturamides A (86) and B (87) [70], gallinamide A (88) [71], carbamin A (89) and dragomabin 
(90) [72], dragonamide E (91) [73], viridamides A (92) and B (93) [74]. 
 
Table 2.3: Marine cyanobacterial secondary metabolites with promising anti-infective activities. 
 
                
                                              84. Calothrixin A                                    86. Venturamide A                             87. Venturamide B 
                                             85. Calothrixin B N5-deoxy 
 
 
88. Gallinamide A 
 
89. Carbamin A 
 
90. Dragomabin 
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91. Dragonamide E. 
 
 
92. Viridamide A. 
 
 
93. Viridamide B 
 
Despite the lack of documented formal registers on marine cyanobacteria, exists the precise 
knowledge about the occurrence of CyanoHABs in San Andres Island in the Colombia Caribbean 
Sea. For this reason we decide to investigate and evaluate the toxicity of some of the 
cyanobacterial strains involved in this blooms occurred in October 2009 and July 2010, by means 
of the Artemia salina lethality assay to have an indication of the potential risks. And also based on 
the previously shown importance as a source of novel bioactive secondary metabolites, is the aim 
of this work, also to evaluate them an as anticancer against several cancer cell lines and the 
antileishmanial activity of crude extracts of these Colombian cyanobacteria, which constitutes in 
the pioneering work in Colombia in evaluating this unexplored resource of marine natural 
products. 
 
2.3. Experimental section 
 
2.3.1. Collection of cyanobacteria samples 
 
The marine cyanobacterial samples were collected from by SCUBA diving at the Pinaculos (5 m 
deep), Felipe’s Place (15 - 20 m deep) and El Planchon (25 - 28 m deep) locations in the Old 
Providence Island, and from El Faro (10 - 12 m deep) at San Andres Island in the Colombian 
Caribbean Sea in October 2009 and July 2010 during events of CyanoHABs in those locations. 
Collections were done by Professor Mónica Puyana and Julian Prato (Cand. MSc.) from 
Universidad de Bogotá Jorge Tadeo Lozano and by Professor Freddy Ramos from Universidad 
Nacional de Colombia. The samples were stored in sea water and frozen at -10 °C until extraction. 
Voucher samples were separated and conserved in glycerol to carry out the morphological and 
molecular characterization of all mats. 
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2.3.2. Extraction of samples 
 
Previous to extraction the cyanobacterial material was freeze dried and the resulting material was 
subjected to an extraction with a mixture of CH2Cl2/CH3OH 1:1 three times. The extract was 
filtered and concentrated to dryness in vacuo to give the crude extract  
 
2.3.3. Evaluation of toxicity of cyanobacterial extracts by Artemia 
salina lethality assay 
 
Brine shrimp Artemia salina toxicity assay was performed as previously reported [75]. After a 48 h 
hatching period in artificial sea water (3.8% of marine salt) at 26-30 °C, among 10-15 nauplii were 
placed in each well of a 24-well plates using the minimum amount of artificial sea water. Then 
two millilitres of the extract solutions were placed in each well. The extracts were evaluated at 
concentrations of 1000, 500, 100, 10, 1 and 0.1 ppm, which were dissolved employing a mixture 
of 30 µL of DMSO and 20 µL of acetone. Each extract was evaluated by triplicate. After 24 h the 
live and dead shrimp were tallied and LC50 was calculated using the method of Reed-Munchen 
[75]. 
 
2.3.4. Leishmanicidal activity of cyanobacterial crude extracts 
 
 Cell cultures 
 
The cell line of murine origin (J774.A2), as well as Leishmania panamiensis parasites were 
cultivated in RPMI 1640 medium (Gibco BRL-Life Techonologies Inc. Grand Island, NY) 
supplemented with 2mM L-glutamine (Gibco BRL-Life Techonologies Inc. Grand Island, NY), 1% 
non-essential amino acids, 1000 U/mL penicillin, 0.1 mg/mL streptomycin, 0.25 µg/mL 
amphotericin B (Sigma Chemical Co, St. Louis, MO), 24 mM sodium bicarbonate (Sigma), 25 mM 
HEPES (Gibco) and 10 fetal bovine serum (FBS, Microgen, Bogotá, Colombia) 
 
 Cytotoxicity assays 
 
In order to determine the cytotoxic effects of crude extracts from marine cyanobacteria assays on 
murine macrophages (J774.A2) were carried out. To perform this, 0.1 mL per well of a suspension 
with 1 × 104 cells/mL in RPMI 1640 medium were seeded in 96-well plates. After 24 h of 
incubation aliquots of solutions of each extract at 5 different concentrations were poured into 
the wells and the cells were exposed during 72 h. The assays included control wells containing the 
solvents employed to dissolve the extracts (DMSO and EtOH), the drugs usually employed for 
treatment of leishmaniasis (pentamidine), cells without the extracts and cells with culture 
medium only. After exposure period, cell viability was evaluated according to literature [76]. 
Resazurin at 44 mM (Sigma Aldrich, USA) was added to each well with the aim to evaluate the 
metabolic activity of cells. After an additional period of incubation of 4 h, arbitrary fluorescence 
units (AFU) were measured using a spectrofluorometer (Tecan Genius Plate Reader) and 
Magellan® Software. Fluorescence obtained from the wells containing untreated cells not 
exposed to any of the controls was considered as 100% feasibility. The lectures obtained from the 
other treatments were measured with respect to this 100% according to the following formula: % 
viability at X concentration = (AFU at X concentration × 100)/AFU from cells under normal growth 
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conditions not exposed to any treatment. These percentages were then exported to the 
GraphPad Prism 5 Demo Software (GraphPad Software, Inc, La Jolla, CA, USA) to plot a 
concentration-response curve and obtain the media cytotoxic concentration (LC50), which 
corresponds to the concentration of extracts that produces death in 50% of the exposed cells. 
The assays were made three times, each by duplicate. 
 
 Effectiveness assays on extracellular forms of Leishmania panamiensis 
 
Suspensions of L. panamiensis, at 2 × 105 promastigotes/mL were incubated during 72 h at 
different concentrations starting at the half of LC50 calculated previously in cytotoxicity assay. 0.1 
mL of parasite cultures were seeded on 96-well flat-bottom plates (TPP Tissue Culture Labware, 
Switzerland) and incubated at 26 °C in RPMI 1640 medium. Parasite viability was assessed by 
adding 44 mM of Alamar Blue dye to each well and incubating plates again for 48 h at 26 °C. 
Arbitrary fluorescence units derived from resazurin, were measured using a Genius Tecan 
spectrofluorometer. 100% of viability was considered from AFU measured from wells containing 
promastigotes not exposed to any treatment. In that sense, readings from each of the treatments 
were processed with respect to 100% viability according to the formula: % viability at X 
concentration = (AFU at X concentration × 100)/AFU from parasites grown under normal 
conditions and not exposed to any extract. Data were processed using the GraphPad Prism 5 
Demo Software (GraphPad Software, Inc, La Jolla, CA, USA) obtaining a concentration-response 
curve and determine the median effective concentration (EC50), which corresponds to extract 
concentration at which death is induced on 50% of the exposed parasites. The assays were made 
three times, each by duplicate. These assays were conducted at Immunotoxicology Research 
Group of Professor Gabriela Delgado (Departamento de Farmacia-Universidad Nacional de 
Colombia-Bogotá) by Ph.D. candidate Diana Granados 
 
2.3.5. Evaluation of cytotoxic activity against several cancer cell lines 
 
 Cell lines 
 
Five human tumor derived cell lines obtained from the Cell Bank of the Immunology Laboratory at 
the Colombian National Institute of Cancerology (INC) were used. A549 (lung cancer), MDA-MB-
231 (breast cancer), MCF-7 (breast cancer), HeLa (cervix carcinoma) and PC3 (prostate cancer). All 
cell lines were maintained in Eagle´s minimal essential medium (MEM) with 5% of fetal bovine 
serum (FBS), 100 UI/mL penicillin and 100 µg/mL streptomycin. Cultures were held in 75 cm2 
culture flasks at 37 °C, 5% CO2 and 100% relative humidity, changing media at least twice a week. 
 
 Cytotoxic activity evaluation 
 
Culture flasks in a 90% confluence were tripsinized and counted in Neubauer chamber using blue 
exclusion procedure. Cell were inoculated into 96 well microtiter plates at plating densities 
ranging from 5,000 to 40,000 cells/well depending on the doubling time of individual cell lines. 
After cell inoculation, the microtiter plates were incubated at 37 °C, in a constant humidified 
atmosphere of 5:95 CO2/air during 24 h for attachment. Extracts were dissolved in dimethyl 
sulfoxide (DMSO) at concentration of 62,500 µg/mL as a stock solution and conserved at 4 °C. 
Three solutions were prepared from the stock solution at 1.25, 12.5 and 125 µg/mL. Maximum 
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concentration of DMSO in wells was 0.1% v/v. Doxorubicin hydrochloride was used as positive 
control at concentrations of 0.1, 1.0 and 10 µg/mL, and MEM plus DMSO was used as blank. 
 
Treatments were added and plates were incubated for 48 h at 37 °C, 5% CO2, 95% air and 100% 
relative humidity. Then a solution of medium without SBF, with AB and Alamar Blue (resazurin, 1 
mL per 9 mL of medium) was added to each well, and incubated again for 4 h. After that plates 
fluorescence derived from resazurin was read using a Genius Tecan spectrofluorometer. 
Inhibition was determined as decrease of fluorescence relative to fluorescence of control cultures 
and plotted against extract concentration and IC50 values calculated. 
 
GraphPad Prism 4.0 was used to calculate LC50 values by nonlinear regression and compare them, 
by ANOVA analysis followed by Tukey Test, with 95% confidence. These assays were conducted at 
the Cancer Pharmacogenetics Research Group Laboratories of Professor Fabio Aristizabal 
(Departamento de Farmacia-Universidad Nacional de Colombia-Bogotá) by undergraduate 
students Michael Ramírez and Adriana Camargo. 
 
2.4. Results and discussion 
 
A total of 27 cyanobacterial samples were collected and extracted. The morphological 
identification of the samples is being carried out actually by Julian Prato (Cand. M.Sc. 
Microbiology from Universidad Nacional de Colombia), and preliminary results obtained up to 
now for some of the samples are shown in table 2.1. 
 
Table 2.4: Marine cyanobacteria strains collected at San Andres and Old Providence Islands. 
 
Strain 
code 
Morphological identification 
Crude 
extract (g) 
Strain 
code 
Morphological identification 
Crude 
extract (g) 
PNM1 - 0.82 PNM15 Symploca hydnoides and Phormidium sp. 1.81 
PNM2 - 0.09 PNM16 Symploca hydnoides and Phormidium sp. 0.60 
PNM3 - 0.07 PNM17 - 0.92 
PNM4 - 0.04 PNM18 - 0.15 
PNM5 
Lyngbya majuscula and Oscillatoria 
margaritifera 
0.42 PNM19 Symploca hydnoides and Phormidium sp. 1.69 
PNM6 
Symploca hydnoides and Phormidium 
submembranaceum 
2.65 PNM20 Symploca hydnoides and Phormidium sp. 1.42 
PNM7 Oscillatoria nigroviridis 11.27 PNM21 - 0.87 
PNM8 
Lyngbya sp. and Oscillatoria 
margaritifera 
11.42 PNM22 - 1.34 
PNM9 
Lyngbya sp. and Oscillatoria 
nigroviridis 
5.80 PNM23 - 1.68 
PNM10 
Blennothrix glutinosa and Lyngbya 
sp. 
0.62 PNM24 - 1.92 
PNM11 - 2.74 PNM25 - 0.73 
PNM12 - 1.42 PNM26 - 1.33 
PNM13 Symploca hydnoides 2.72 PNM27 - 2.43 
PNM14 Lyngbya spp and Oscillatoria sp. 2.49    
 
It is clear from these data that just 1 out of the 27 cyanobacteria samples consist of one single 
strain, sample coded as PNM07 of O. nigroviridis. The other samples are composed by two or in 
some cases even more species of cyanobacteria. It is to note that this morphological 
identification is not definitive as the morphological features such as growth form, coloration and 
cell sizes are affected by environmental factors, making the identification to the species level 
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based on morphological characters difficult. However, this identification is a preliminary stage in 
the whole process of identification, previous to the molecular identification by 16S rRNA gene 
sequencing which will be carried out later on. It can be seen also the very low yield of crude 
extracts obtained for some of the samples, because although was considered to have been 
collected enough material, it resulted to be small amounts in part due to the presence of sand. 
This fact, of the very low yields of extraction, was one limitation for not to test all the samples for 
theis biological activity, and was one of the criteria used to select the sample to be studied. 
 
Table 2.5 summarizes the results of all the biological activities evaluated on the crude extracts. 
For the toxicity assays against A. salina 17 out of 27 samples were tested. The obtained results, 
according to literature in which an extract is consider toxic if its LC50 value is below 500 ppm [77, 
78], showed that from the evaluated extracts, 12 exhibited significant toxicity to A. salina with 4 
of them extremely toxic with values below 100 ppm, 3 out of the 17 were moderately toxic with 
values between 500-1000 ppm, and 2 were not toxic with LC50 values above 1000 ppm. This 
bioassay has been widely used to evaluate the toxicity of freshwater, terrestrial and symbiotic 
cyanobacteria [54, 55, 77, 78] and also of marine cyanobacteria [56, 79]. These results shows the 
predominance of toxic species in the cyanobacterial blooms of San Andres and Old Providence 
Islands, as demonstrated by the 71% of toxic samples, compared with the proportion of 10-25% 
of toxic species reported in other studies [54, 55, 77, 80]. 
 
A. salina bioassay may be employed as a preliminary tool to evaluate toxic effects on marine 
ecosystems, as this organism is representative specie of zooplankton [56]. This assumption is 
supported for some reports in which cyanobacterial toxins are harmful to invertebrates or cause 
feed deterrence by grazers, suggesting an ecological role [81-83]. This rapid and inexpensive 
bioassay has also been employed for chemical studies on marine cyanobacteria [84-86]. 
 
Due to experimental difficulties to carry out the anti-leishmanial bioassay to all extracts, PNM7, 
PNM10, PNM11 and PNM14 samples were selected to evaluate the activity based on their potent 
activity in the A. salina lethality assay and also on the amount of extract which were manageable 
for subsequent chemical studies (Table 2.5). The extracts selected for anti-leishmanial bioassay, 
were not active against the parasites, but they showed high cytotoxic activity against murine 
macrophages with LC50 values below 100 µg/mL. 
 
With respect to the anticancer assays, all the 27 samples were evaluated against the five human 
cancer cell lines (Table 2.5). Two samples (PNM8 and PNM27) out of the 27 extracts were active 
against the five cell lines with IC50 values all below 100 µg/mL, showing high cytotoxicity for the 
crude extracts. PNM2 was active against three out of the five cancer cell lines with IC50 values 
below 100 µg/mL. Finally, with exception to PNM1, PNM9, PNM12 and PNM21, which were not 
active to any cell line, all the other extracts, were active to at least one cancer cell line, being 
most of them active against HeLa cellular line with LC50 values ranging from <1 to approximately 
100 µg/mL. It is to note that cytotoxicity must be also evaluated on primary cell lines, as for 
example skin fibroblast cell line, in order to determine if the observed efect is selective to cancer 
cell lines, but not to these normal cells, as a desirable result. 
 
Although traditionally A. Salina lethality bioassay has been used to carry out preliminary cytotoxic 
screenings, due to correlations between these two bioassays as mentioned in literature [87], 
some of the recent results about cyanobacterial crude extracts screenings against A. Salina do not 
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follow this accepted rule, demonstrating that in fact a conclusion about cytotoxic activity from an 
active to A. Salina extract cannot be assumed [55, 77, 80, 88], neither for compounds as in the 
case of lyngbyacyclamides A and B which showed high toxicity to B16 mouse melanoma cells with 
IC50 of 0.7 µM, but did not show toxicity to A. salina nauplii at 70 µM [89]. This fact is explained 
because the toxic effects in single eukaryotic cells, targets to various basal metabolic pathways, 
rather than being a specific mechanisms against a complex multi-cellular organism. For the 
precise case of the results presented herein, this premise is not either accomplished, as for 
example the extracts with no or low toxicity to A. Salina were active against any of the cancer cell 
lines like extract PNM6 or PNM15, and also some of the most toxic were not as active against the 
cancer cells like PNM9. 
 
Due to the toxicity showed to A. salina by sample PNM7 of Oscillatoria nigrovidiris, and the 
amount of crude extract obtained, this cyanobacteria was selected to perform chemical studies in 
order to isolate the responsible compounds of its toxicity and evaluate its activity in the bioassays 
previously described, which results are going to be presented in the next chapter. 
  
 
Table 2.5: Results of the evaluation of biological activity of marine cyanobacteria extracts. 
Sample 
Toxicity 
Artemia 
salina 
LC50 (ppm) 
Antileishmanial activity 
 
 
Cytotoxic activity 
 
Murine macrophages 
LC50 (µg/mL)
a
 
L. panamiensis 
promastigotes 
EC50 (µg/mL)
a 
 
A549 
IC50 (µg/mL)
a
 
MDA MB231 
IC50 (µg/mL)
a
 
MCF-7 
IC50 (µg/mL)
a
 
HeLa 
IC50 (µg/mL)
a
 
PC3 
IC50 (µg/mL)
a
 
PNM1 >1000 NT NT  NA NA NA NA NA 
PNM2 331 NT NT  95.76 (12.5-125) 94.43 (12.5-125) NA 9,725 (1.25-12.5) NA 
PNM3 284,5 NT NT  NA NA NA 4.561 (3.275-6.351) NA 
PNM4 NT NT NT  NA NA NA 10,43 (1.25-12.5) NA 
PNM5 >1000 NT NT  NA NA NA 107.9 (83.56-139.3) NA 
PNM6 897.9 NT NT  NA NA NA < 1 NA 
PNM7 4.5 82.4 (45.73-148.6) ND  NA NA NA 9,812 (1.25-12.5) NA 
PNM8 169.8 NT NT  37.01 (15.22-89.35) 62,34 (1.25-12-5) 49.13 (18.47-130.7) 36.75 (18.85-71.65) 75,62 (1.25-12.5) 
PNM9 274.4 NT NT  NA NA NA NA NA 
PNM10 39.9 21.4 (8.535-53.87) ND  NA NA NA 0.4163 (0.067-2.55) NA 
PNM11 1.7 105.4 (97.37-114.1) ND  NA NA NA 22.55 (12.09-42.08) NA 
PNM12 218.1 NT NT  NA NA NA NA NA 
PNM13 214.6 NT NT  NA NA NA 2.043 (1.024-4.072) NA 
PNM14 4.1 42.9 (24.59-74.68) ND  NA NA NA < 1 (<1) NA 
PNM15 689.1 NT NT  NA NA NA 37.80 (25.30-56.49) NA 
PNM16 661.5 NT NT  NA NA NA 33.17 (19.21-57.29) NA 
PNM17 123.6 NT NT  NA NA NA 68.59 (12.5-125) NA 
PNM18 138.8 NT NT  NA NA NA 1.509 (4.639-5.404) NA 
PNM19 NT NT NT  NA NA NA 4.88 (4.611-5.164) NA 
PNM20 NT NT NT  NA NA NA 5.463 (3.650-8.175) NA 
PNM21 NT NT NT  NA NA NA NA NA 
PNM22 NT NT NT  NA NA NA < 1 NA 
PNM23 NT NT NT  NA NA NA 9.224 (6.293-13.52) NA 
PNM24 NT NT NT  NA NA NA 5.846 (1.404-24.33) NA 
PNM25 NT NT NT  NA NA NA 1.182 (1.929-5.177) NA 
PNM26 NT NT NT  NA NA NA < 1 NA 
PNM27 NT NT NT  19.39 (3.358-112.0) 20,25 (12.5-125) 37.79 (30.57-46.70) 73,51 (12.5-125) 62,48 (12.5-125) 
control          
Pent - 7×10-4  (2×10-4-3×10-3) 
6×10-5 (5×10-5 - 8×10-
5) 
 - - - - - 
Doxo - - -  6.012 (0.8033-45.00) 10.3 (3.592-29.55) 4.302 (0.6804-27.20) 0.9881 (0.8213-1.189) 
0.8919 (0.09391-
8.470) 
NT = No Tested; ND = No Determined; NA = No Active; Pent = Pentamidine; Doxo; Doxorrubicine; a confidence intervals in parenthesis. 
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3 Isolation and identification of compounds from 
the marine cyanobacterium Oscillatoria 
nigroviridis collected at San Andres Island 
 
3.1. Introduction 
 
3.1.1. Morphological description 
 
Oscillatoria nigroviridis sample was found growing over the substrate as a very dark green mat. 
This mat revealed loose and very fragile trichomes. The collected sample was composed mainly 
by just one morphotype (more than 95% of filaments presents in the mat). O. nigroviridis has 
isopolar filaments without mucilage sheat, generally with rounded conic extremes without 
calyptras. Thrichomes were 12 ± 1.3 µm width and 3.5 ± 1.5 µm length. 
 
3.1.2. Chemistry of Oscillatoria genus 
 
Oscillatoria genus belongs to Oscillatoriales order, which is the third major contributor of 
secondary metabolites from marine cyanobacteria with 9%, after Lyngbya (35%) and Nostoc 
(11%) genera (figure 1.2) [42]. Up to 2010, from the genus Oscillatoria has been isolated 
approximately 64 compounds, and the distribution among the different species, which can be 
seen in figure 3.1, is more equitable as compared to other genera; around 30% comes from 
undetermined species, 28% from Oscillatoria agardhii, 19% from Oscillatoria nigroviridis, and 13% 
from Oscillatoria spongelia. Oscillatoria raoi and Oscillatoria acutissima count for 3% each one 
and Oscillatoria rosea and Oscillatoria amphibian for 2% (figure 3.1) [42]. 
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Figure 3.1: Percentage distribution of cyanobacterial metabolites obtained from Oscillatoria 
genus. Figure taken from reference 42. 
 
One of the first reported compounds isolated from Oscillatoria specie were debromoaplysiatoxin 
(94), together with oscillatoxin A (95) and three brominated toxins (96-98) [90]. This aplysiatoxins 
class of compounds had been previously isolated from the mollusk Stylocheilus longicuada [91] 
that feeds preferentially on Lyngbya majuscula, and those toxins were found to be the causative 
agents of severe contact dermatitis that in some occasions affected swimmers. 
Debromoaplysiatoxin was found to display antineoplastic activity, and the other aplysiatoxins and 
oscillatoxin A were found to be powerful tumor promoters [92]. Ten years after their isolation, 
Moore et al [93] could finally determine the absolute configuration of these molecules by means 
of optical, NMR and X-ray crystallographic analysis. 
 
From diverse collections around the world of the cyanobacterium Oscillatoria agardhii have been 
isolated several compounds. For example, from a freshwater lake in Scotland were isolated two 
(Z)-dehydrobutyrine(Dhb)-containing hepatotoxic microcystins [D-Asp3, (Z)-Dhb7]microcysitin-
HtyR (99) and [D-Asp3, (Z)-Dhb7]microcysitin-LR (100) [93]. Several studies carried out in Japan on 
this specie have led to the isolation of a variety of compounds among which are the serine 
protease inhibitors glycopeptides aeruginosins 205-A (101) and –B (102). Their planar structures 
were obtained by extensive MS and 2D-NMR studies and their absolute stereochemistry by HPLC 
analysis of Marfey´s derivates and chiral gas chromatography. Both compounds have the same 2D 
structures but differ in the absolute configurations of 3-hydroxyleucine (Hleu) and phenyllactic 
acid 2-O-sulfate (Plas) [94]. 
 
The first members of anabaenopeptin series of compounds were isolated from the 
cyanobacterium Anabaena flos-aquae and from the cultured cyanobacterium O. agardhii were 
isolated anabaenopeptins E (103) and F (104) with an unusual ureido bond and 7-
methylhomotyrosine (7-Mhty) or homotyrosine (Hty), respectively [95]. From this 
cyanobacterium was also isolated Oscillapeptin G (105), a cyclic depsipeptide with potent 
tyrosinase inhibition activity a culture of this toxic freshwater cyanobacterium. Oscillapeptin G, a 
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compound containing glyceric acid and the non-proteinogenic aminoacids homotyrosine and Ahp 
(3-amino-6-hydroxy-2-piperidone), also found in several cyclic depsipeptides isolated initially 
from the sea hare Dolabella auricularia [96]. From other two different cultures of this 
cyanobacterium the unique cyclic peptides prenylagaramides A (106) and B (107) were obtained, 
containing a rare O-prenyltyrosine (Ptyr). These compounds showed no activity against proteases 
such as trypsin, thrombin, plasmin, chymotrypsin, elastase, leucine amino peptidase and papain 
and were neither cytotoxic against P-388 leukemia cells, nor active against several Gram-positive 
and Gram-negative bacteria [97]. 
 
A series of polychlorinated peptides, dysideaproline A-F (108-113) isolated initially from the 
sponge Dysidea sp., have been proved to be truly produced by the filamentous cyanobacterial 
symbiont Oscillatoria spongeliae, by means of different techniques such as cell separation and 
catalyzed reporter deposition fluorescence in situ hybridization (CARD-FISH) which allowed to 
establish that the symbiont possess the genes involved in the biosynthesis of chlorinated leucine 
precursors [38, 98], or by a modern and revolutionary instrumental technique called “natural 
product MALDI-TOF-imaging” (npMALDI-I) in which can be determined the spatial distribution of 
secondary metabolites between the sponge and the cyanobacterium, attributing to the latter the 
production of these metabolites [99]. 
 
From a single strain of the marine cyanobacterium Oscillatoria sp., were isolated seven 
depsipeptides named largamides A-G (114-120), and one cyclic peptide called largamide H (121). 
Their structures were assessed by extensive nuclear magnetic resonance spectroscopic analysis, 
including 2D NMR experiments such as DQF-COSY, HOHAHA, HMBC, HSQC and ROESY, as well as 
ESI-MS analysis. The absolute configuration of the amino acids was established by advanced 
Marfey’s method, chiral HPLC, and combined analysis of homo and heteronuclear 2,3J couplings, 
and ROE data. All these eight compounds represent three different structural classes. For 
instance, largamides A-C are characterized by the unusual occurrence of tiglic acid unit, while 
additionally to this largamides B and C possess the rare 2-amino-5-(4’-hydroxyphenyl)pentanoic 
acid (Ahppa) and 2-amino-6-(4’-hydroxyphenyl)hexanoic acid (Ahpha), respectively. Largamides 
D-G contain 3-amino-6-hydroxy-2-piperidone acid (Ahp), in addition to Ahppa unit. And finally, 
largamide H displays the 2,5-dihydroxylated β-amino acid moiety derivative of Ahppa, and two 
residues of the non proteinogenic amino acid 2,3-dehydro-2-aminobutanoic acid (Dab) [100, 101]. 
 
Venturamides A (86) and B (87), two cyclic hexapeptides were isolated from a Panamanian 
Caribbean strain of marine cyanobacterium Oscillatoria sp., and constituted the first report of 
marine cyanobacterial metabolites with selective anti-malarial activity against the W2 
chloroquine-resistant strain Plasmodium falciparum. They were tested for their activity against 
other tropical infectious diseases such as leishmania and Chagas disease, but showed mild 
activity. Venturamide B is one of the very few compounds which possess an uncyclized hydroxy 
amino acid [70]. 
 
Two hybrid PKS-NRPS derived compounds were isolated and identified from Oscillatoria 
nigroviridis collected at Curacao, termed viridamides A (92) and B (93). These secondary 
metabolites are characterized for their high degree of N-methylation, and also for having the 
structurally novel moiety 5-methoxydec-9-ynoic acid and an unusual proline methyl ester 
terminus. They were tested for their activity against trypanosomiasis and leishmania disesases. 
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Only viridamide A was active with an IC50 of 1.1 µM and 1.5 µM, against Trypanosoma cruzi and 
Leishmania mexicana, respectively [74]. 
 
From a mixed assemblage of Symploca sp. and Oscillatoria cf. sp., collected in Papua New Guinea, 
the hoiamide B (81) was isolated, together with the hoiamide A previously reported from an 
assemblage of Lyngbya majuscula and Phormidium gracile. This cyclic depsipeptide is 
characterized by possessing an acetate extended and S-adenosyl methionine modified isoleucine 
unit, a triheterocyclic system composed of two α-methyl thiazolines and one thiazole, and a higly 
oxygenated and methylated C-15 polyketide unit. The absolute stereochemistry of the 16 chiral 
centers was assigned by various methods, including degradation reactions, chromatographic 
analysis and NMR spectroscopic studies. Hoiamide B showed activity in neocortical neurons, 
stimulating sodium influx and suppressed spontaneous Ca2+ oscillations with EC50 values of 3.9 
µM and 79.8 nM, respectively [65, 66]. 
 
Palmyrolide A (82) is a neuroactive macrolide isolated from an assemblage of two genera of 
filamentous marine cyanobacteria composed of Leptolyngbya cf. and Oscillatoria spp. It possesses 
a rare N-methyl enamide and an unusal t-butyl branch. It exhibited significant suppression of 
calcium influx in cerebrocortical neurons with an IC50 of 3.70 µM, and also a relatively potent 
sodium channel blocking activity in neuro-2a cells with an IC50 value at 5.2 µM, without 
appreciable cytotoxicity [67]. 
 
Two new molluscicidal metabolites thiopalmyrone (122) and palmyrrolinone (123) have been 
recently isolated from an assemblage of cyanobacteria cf. Oscillatoria and Hormoscilla spp. from 
Palmyra Atoll at the Central Pacific Ocean. They exhibited potent activity against Biomphalaria 
glabrata, the snail responsible of schistosomiasis, with LC50 values of 8.3 and 6.0 µM, respectively. 
Interestingly, a small increment in the activity was observed when the compounds were used as 
an equimolar mixture, with a LC50 value at 5.0 µM [102]. 
 
A group of cytotoxic cyclodepsipeptides called veraguamides A-C and H-L (124-131), were isolated 
from cf. Oscillatoria margaritifera strain, collected at Coiba National Park in the pacific ocean of 
Panama. Their structures were elucidated by extensive 2D NMR studies and MS/MS2/MS3 
techniques. Some of these compounds are characterized for having the unique terminal alkynyl 
bromide moiety, just only reported previously in jamaicamide A. From all these compounds, 
veraguamide A was the most active agains H-460 human lung cancer cell line with a LD50 of 141 
nM [103]. 
 
By means of NMR-guided fractionation of two independent collections, of Lyngbya majuscula 
from Papua New Guinea and Oscillatoria sp. from Panama, were isolated serinolamide A (132) 
and propenediester (133), which constitutes new marine compounds with cannabinomimetic 
activity. Serinolamide A showed moderate agonist effect and selectivity for the CB1 cannabinoid 
receptor (Ki = 1.3 µM, >5-fold). This CB1 and CB2 receptors, have very important interest in 
neuropharmacological research, as these constitutes attractive pharmacological targets for 
treatment of several human affections such as cancer, chemotherapy relief, neuropathic pain, 
neurotrauma and appetite regulation [104]. 
 
As could be seen, Oscillatoria genus represents a rich source of secondary metabolites with a 
variety of bioactivities, constituting important organisms to be studied. And although there have 
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been studied some species of this genus in near areas to Colombian Caribbean Sea, it is expected 
that the selected specie Oscillatoria nigroviridis, due to the variation of geographical location, 
may produce different compounds. 
 
Table 3.1: Secondary metabolites isolated from different species of Oscillatoria genus. 
 
Organism Compound 
Biological 
activity 
Ref. 
Oscillatoria 
nigroviridis 
 
94. Debromoaplysiatoxin R1=CH3; R2, R3, R4=H 
95. Oscillatoxin A R1=CH3; R2=Br; R3, R4=H 
96. R1=H; R2=Br; R3,R4=H 
97. R1=H; R2, R3=Br; R4=H 
98. R1=CH3; R2, R3=Br; R4=H 
Dermatotoxic, 
antineoplastic, 
tumor 
promotion 
90-92 
Oscillatoria 
agardhii 
 
99. [D-Asp3, (Z)-Dhb7]microcysitin-HtyR R1=CH3; R2=H; X=CH2CH2-p-OH-Ph 
100. [D-Asp3, (Z)-Dhb7]microcysitin-LR R1=CH3; R2=H; X=CH2CH2CH(CH3)2 
 
Hepatotoxic 93 
Oscillatoria 
agardhii 
(NIES-205) 
 
101. Aeruginosisn 205-A L-Plas, (2R, 3R)-Hleu 
102. Aeruginosin 205-B D-Plas, (2S, 3R)-Hleu 
Serine protease 
inhibitors 
94 
Oscillatoria 
agardhii 
(NIES-204) 
 
103. Anabaenopeptin E R1=CH3; R2=CH3; X=Arg 
104. Anabaenopeptin F R1=CH2CH3; R2=H, X=Arg 
No activity 95 
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Oscillatoria 
agardhii 
 
105. Oscillapeptin G. 
Tyrosinase 
inhibitor 
96 
Oscillatoria 
agardhii 
 
 
106. Prenylagaramide A 
107. Prenylagaramide B. 
No activity 97 
Oscillatoria 
spongeliae 
 
108. Dysideaproline A R1=H; R2=CH3; X, Y=Cl 
109. Dysideaproline B. R1, R2=CH3; X, Y=Cl 
110. Dysideaproline C R1, R2=H; X, Y=Cl 
111. Dysideaproline D R1, X=H; R2=CH3; Y=Cl 
112. Dysideaproline E R1, Y=H; R2=CH3; X=Cl 
113. Dysideaproline F R1=H; R2=CH3; X=Cl; Y=ClH 
No activity 
38, 98, 
99 
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Oscillatoria 
sp. 
 
114. Largamide A. R= L-Leu 
115. Largamide B. R=  L-Ahppa 
116. Largamide C. R=  L-Ahpha 
 
 
117. Largamide D. X=Br; R=  L-Leu 
118. Largamide E. X=Cl; R=  L-Leu 
119 Largamide F. X=Br; R= L-Tyr 
120. Largamide G. X=Br; R=  L-hTyr 
 
 
121. Largamide H. 
Chymotrypsin 
inhibitors 
100, 
101 
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Oscillatoria 
sp. 
           
                        86. Venturamide A                               87. Venturamide B. 
Anti-malarial 
against W2 
chloroquine 
resistant 
Plasmodium 
falciparum 
70 
Oscillatoria 
nigroviridis 
 
92. Viridamide A.
 
93. Viridamide B. 
Antileishmanial 74 
Assemblage 
of Symploca 
sp. and 
Oscillatoria 
cf sp. 
 
81. Hoiamide B 
Neurotoxic 66 
Assemblage 
of 
Leptolyngbya 
cf and 
Oscillatoria 
spp 
 
82. Palmyrolide A. 
Neuroactive 67 
Assemblage 
of 
Oscillatoria 
and 
Hormoscilla 
spp         
                           122. Thiopalmyrone                        123.Palmyrrolinone 
Molluscicidal 
against 
Biomphalaria 
glabrata 
102 
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cf 
Oscillatoria 
margaritifera 
 
124. Veraguamide A.  
125. Veraguamide B R1= ; R2=CH3 
126. Veraguamide C R1= ; R2=CH2CH3 
127. Veraguamide H R1= ; R2=CH3 
128. Veraguamide I R1=CH2CH3; R2=CH2CH3 
129. Veraguamide J R1=CH2CH3; R2=CH3 
 
 
130. Veraguamide K R=CH3 
131. Veraguamide L R=H 
Cytotoxic 103 
Oscillatoria 
sp. 
 
 
132. Serinolamide A 
 
133. Propenediester. 
Neuroactive 
selective 
agonist of CB1 
cannabinoid 
receptors 
104 
 
3.2. Experimental section 
 
3.2.1. General experimental procedures 
 
Optical rotations were measured on a Polartronic E, Schmidt+Haensch polarimeter. NMR data of 
fractions were recorded on a Bruker Avance 400 MHz spectrometer (400 and 100 MHz for 1H and 
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13C NMR, respectively) in CDCl3, with solvent residual signals as internal standard (δH 7.26). NMR 
spectra of pure compounds were acquired on a Varian Unity INOVA 400 MHz and on a Varian 
Oxford 600 MHz spectrometers in methanol-d4, using residual solvent signals as internal 
standards (δH 3.31 and 4.87, δC 49.1), and multiplicities of carbon resonances were determined by 
HSQC spectra. High-resolution mass spectral data were obtained using the Thermo Scientific 
Instruments LTQ Orbitrap XL Hybrid Fourier Transform mass spectrometer Discovery system 
coupled to a Thermo Instruments HPLC system (Accela PDA detector, Accela PDA autosampler, 
and Accela pump). The following conditions were used: capillary voltage 45V, capillary 
temperature 260 °C, auxiliary gas flow rate 10-20 arbitrary units, sheat gas flow rate 40-50 
arbitrary units, spray voltage 4.5 kV, mass range 100-1000 amu (maximum resolution 30000). 
Flash column chromatography (FCC) was performed using silica gel (0.043-0.060 µm, Merck®). 
Solid phase extraction was made using LiChrolut® RP-18 (40-63 µm cartridges, Merck®). HPLC 
separation was carried out on a Merck-Hitachi 6000 instrument equipped with a Merck-Hitachi L-
6200A pump and a DAD L-4500 detector. HPLC profiles were made on a Phenomenex 
Lichrosphere® reversed phase (RP-18, 250 × 4.6 mm, 5 µm, 100 Å) column. Compounds were 
purified using a LiChroCART® LiChrospher® reversed phase (RP-18, 250 × 10 mm, 10 µm) column, 
and a Waters XTerra® reversed phase (RP-18, 250 × 4.6 mm, 5 µm) column, with detection at 210 
nm. All solvents were either distilled or HPLC gradient. 
 
3.2.2. Cyanobacterium collection 
 
The Oscillatoria nigroviridis sample (PNM8) was collected in October 2009 at San Andres Island by 
SCUBA diving. The specimens were stored in sea water and kept frozen at -10 °C until extraction. 
Voucher samples were separated to carry out identification by morphological and molecular 
characteristics. 
 
3.2.3. Extraction and purification 
 
The extract was obtained as was previously described in chapter 2 (page XX), was filtered and 
concentrated to dryness in vacuo to give the crude extract (11.3 g). 7.14 g of the extract were 
fractionated by silica gel-flash column chromatography (FCC) using a step gradient solvent system 
of increasing polarity starting with hexane (100%), then hexane/EtOAc (9:1), hexane/EtOAc (8:2), 
hexane/EtOAc (1:1), hexane/EtOAc (2:8), EtOAc (100%), EtOAc/MeOH (8:2), EtOAc/MeOH (7:3) 
and MeOH (100%), obtaining 9 fractions (FI-FIX). The Artemia salina highly-toxic fraction FVII (480 
mg), eluted with AcOEt/MeOH (8:3), was further separated by C-18 SPE cartridges employing a 
stepwise gradient solvent system of decreasing polarity starting with MeOH/H2O 1:9, then 
MeOH/H2O 2:8, MeOH/H2O 4:6, MeOH/H2O 1:1, MeOH/H2O 6:4, MeOH/H2O 7:3, MeOH/H2O 8:2, 
MeOH/H2O 9:1, MeOH and MeOH/CH2Cl2 1:1 to give 10 subfractions (FVII1-FVII10). Fractions 
FVII6-FVII8 were further purified at first instance by RP-HPLC using a LiChroCART® LiChrospher® 
reversed phase (RP-18, 250 × 10 mm, 10 µm) column, with a gradient from 60% MeOH/H2O to 
100% MeOH over 20 minutes, to obtain enriched fractions of the compounds, which were 
subsequently purified by RP-HPLC employing a XTerra® reversed phase (RP-18, 250 × 4.6 mm, 5 
µm) column, in isocratic mode 50% ACN/H2O acidified with 0.05% formic acid, to yield pure 
compounds C1 to C5. The isolation of these five compounds is presented in figure 3.2 
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Figure 3.2: Isolation diagram employed for the purification of compounds C1 to C5. 
 
3.2.4. Evaluation of toxicity of extract fractions FI-FIX by Artemia 
salina lethality assay 
 
Evaluation of toxicity of fractions obtained by FCC of crude extract, were carried out as stated in 
numeral 2.2.3. 
 
3.2.5. Leishmanicidal activity of fractions FI-FIX 
 
Antileishmanial activity of fractions FI-FIX was evaluated as described previously in numeral 2.2.4 
for crude extracts. 
 
3.2.6. Evaluation of anticancer activity of fractions FI-FIX against 
several cancer cell lines 
 
Cytotoxic assays against A549 (lung cancer), MDA-MB-231 (breast cancer), MCF-7 (breast cancer), 
HeLa (cervix carcinoma) and PC3 (prostate cancer) cell lines, were carried out as described 
previously in numeral 2.2.5 for crude extracts. 
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3.3. Results and discussion 
 
Taken into account that this is the first study carried out in Colombia on marine cyanobacteria, it 
was decided to follow the isolation procedure usually employed in Professor’s Gerwick laboratory 
[103]. 
 
In the process to develop chemical studies on marine cyanobacteria collected in the Colombian 
Caribbean Sea, Oscillatoria nigroviridis sample was selected based on its result on A. salina which 
showed to be highly toxic with a very low LC50 value of 4.5 ppm. So the fractions obtained after 
FCC were screened for bioactive metabolites by their activity in A. salina toxicity and also tested 
in antileishmanial and anticancer assays previously described (table 3.1). 
 
A. salina lethality bioassay-guided screening, showed three contiguous highly toxic fractions FV, 
FVI and FVII with LC50 values at 62, 57 and 3.5 ppm, respectively. A careful revision of the 
published papers shows that these fractions usually contain peptide-like compounds, the most 
common and active compounds produced by cyanobacteria [86]. 
 
From these fractions, FVII was further separated by RP-SPE. NMR guided screening allowed to 
identify fractions FVII6-FVII8 to possess peptide-like compounds due to their profiles in the 1H-
NMR spectrum, with the characteristic shift pattern of nonribosomal peptides with the α-protons 
around 4.0-5.5 ppm and N-methyl groups around 2.5-3.5 ppm. Repetitive RP-HPLC purification of 
these fractions allowed to isolated five compounds C1 (7.2 mg), C2 (3.7 mg), C3 (1.3 mg), C4 (0.9 
mg) and C5 (1.5 mg). 
 
 
Figure 3.3: HPLC isolation chromatogram. XTerra® reversed phase column (RP-18, 250 × 4.6 mm, 
5 µm), isocratic mode 50% ACN/H2O acidified with 0.05% formic acid. 
 
3.3.1. Structural elucidation of compound C1 
 
Compound C1 (7.2 mg) was obtained as an optically active yellow amorphous solid with an optical 
rotation value [α]D = -134.6 (c 0.49, MeOH), with a molecular formula of C37H66N6O6 as 
determined by HRESIMS (observed [M+Na]+ at m/z 713.4906, calculated [M+Na]+ 713.4942, and 
observed [M+H]+ at m/z 691.5092. calculated [M+H]+ 691.5117). Analysis of the 1H-NMR 
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spectrum in CD3OD (table 3.3) revealed the pattern of chemical shifts typical for a peptide with a 
single conformer, that allows NMR structural elucidation as follows: five α-methine proton signals 
at 4.36 ppm (1H, q, J = 7.11 Hz), 4.84 ppm (1H, d), 4.67 ppm (1H, d, J = 9.72 Hz), 4.70 ppm (1H, d, J 
= 11.16 Hz) and 5.22 ppm (1H, d, J = 10.74 Hz), suggesting that C1 was comprised of five amino 
acid residues. Additionally 1H-NMR spectrum showed three sharp singlets at 3.04 ppm (3H), 3.08 
ppm (3H) and 3.19 ppm (3H) indicating the presence of three N-CH3 groups. Together with signals 
for ten C-CH3 groups between 0.70-1.40 ppm, three methylene groups and 11 additional 
methines ranging from 0.95 to 2.89 ppm. Phase-sensitive multiplicity-edited HSQC spectrum 
confirmed the peptidic character of the compound by the five α-CH groups at δC 49.5, 54.1, 59.6, 
61.4 and 63.0 and six amide carbonyl resonances at δC 171.2, 171.4, 172.6, 174.6, 176.8 and 
179.1. Additionally ten C-CH3at δC 10.5, 10.6, 14.9, 15.4, 18.1, 18.2, 18.6, 18.6, 19.4, 19.7, six 
methylenes at δC 18.6, 25.3, 25.5, 27.5, 29.4 and 34.3, which allowed to determine that 6 of the 
1H-NMR signals assigned to methine groups were in fact of three diasterotopic methylenes. The 
three N-CH3 groups were confirmed by the carbon signals at 30.8, 31.0 and 31.3 ppm. Five 
methines at δC 27.5, 28.0 33.1, 37.0 and 37.8 were also identified, counting for 35 out of the 37 
carbons. Analysis of HSQC and gHMBC spectra allowed determining the presence of an acetylenic 
terminal group with carbon resonances at 69.3 and 84.5 ppm, completing the 37 carbons found in 
the molecular formula and suggesting that compound 4 is a linear peptide. Interpretation of 2D-
NMR spectra (gCOSY, TOCSY and gHMBC) afforded the identification of six subunits that 
accounted for all the atoms predicted by the molecular formula as follows (figure 3.3). 
 
Substructure a was deduced as an alanine residue (Ala) mainly by the 1H-1H COSY for C-H proton 
at δ 4.36 (q, J = 7.11 Hz) with the H3-3 methyl doublet at δH 1.30 (d, J = 7.11 Hz), confirmed by the 
HMBC correlations between H-2 and C-3 (δC 18.2), and between H3-3 and C-2 (δC 49.5). 
Substructure b was identified as an isoleucine (Ile) residue from the spin system determined by 
1H-1H COSY and TOCSY that starts at the deshielded doublet α-amino proton H-2 at δ 4.84 
coupled to H-3 multiplet (δH 2.06, δC 33.1), which in turn was coupling with the doublet methyl 
protons of the H3-6 group (δH 0.92, δC 15.4) and with H2-4 diasterotopic methylene protons (δH 
0.95/1.36, δC 25.3). Finally, the HMBC correlation between these H2-4 protons and C-5 methyl at 
δC10.6, allowed establishing the Ile residue. This amino acid was showed to be N-methylated 
because of the HMBC correlations between H-2 and the N-methyl carbon at δC 31.3, and between 
N-methyl protons at δH 3.19 and C-2 at δC 61.4. Partial structure c was also determined as 
isoleucine by means of the 1H-1H correlations between α-proton H-2 at 4.67 ppm (δC 54.1) with 
the protons of isobutyl group characteristic of this amino acid, H-3 (δH 1.92, δC 37.c8), H2-4 (δH 
1.16/1.52, δC 25.5) and H3-6 (δH 0.87, δC 14.9), and by key HMBC correlations between H-3 and H2-
4 protons with C-5 (δC 10.5) allowed to determine the remaining methyl group. 
 
Substructure d showed 1H-1H correlations between H-2 proton at 4.70 ppm (δC 63.0) with an 
isopropyl group, and confirmed by HMBC correlations of H-3 (δH 2.22), H3-4 (δH 0.76) and H3-5 (δH 
0.86) with C-2 carbon at δC 63.0, which are typical for a valine (Val) amino acid residue. This 
residue was determined to be N-methylated because of the HMBC correlations in first instance of 
the N-methyl protons at δH 3.08 with C-2, and between at H-2 proton and NMe carbon at δC 31. In 
a similar way as substructure d, substructure e consisted of an N-methyl valine residue, 
elucidated by the COSY and TOCSY correlations of the doublet H-2 proton (δH 5.22, δC 59.6) with 
H-3 methine proton (δH 2.40, δC 28.0) which in turn was coupling with the two methyl groups H3-4 
(δH 0.93, δC 19.7) and H3-5 (δH 0.87, δC 18.6). This substructure was confirmed by HMBC 
correlations between H-3, H3-4 and H3-5 protons with α-carbon C-2. 
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Table 3.2: Results of the evaluation of biological activity of fractions FI to FIX from O. nigroviridis. 
 
Fraction Toxicity 
Artemia 
salina  
LC50 (ppm) 
Antileishmanial activity  Anticancer activity 
Murine macrophages 
 LC50 (µg/mL)
a
 
L. panamiensis promastigotes  
EC50 (µg/mL)
a 
 
A549 
IC50 (µg/mL)
a
 
MDA MB231  
IC50 (µg/mL)
a
 
MCF-7 
 IC50 (µg/mL)
a
 
HeLa 
IC50 (µg/mL)
a
 
PC3 
 IC50 (µg/mL)
a
 
FI NT NT NA  NT NT NT NT NT 
FII 1.3 95.0 NA  NT NT NT NT NT 
FIII 40.4 234.6 NA  NA NA NA NA NA 
FIV 7.4 101.3 NA  NA NA NA 35.85 (17.09-75.10) NA 
FV 62 NT NA  NT NT NT NT NT 
FVI 57 42.3 NA  NT NT NT NT NT 
FVII 3.5 39.3 NA  62.28 (48.93-
79.27) 
NA 102.2 (12.5-125) 41.66 (32.68-53.10) 102.2 (12.5-125) 
FVIII > 100 79.8 NA  NA NA NA 59.14 (41.10-85.89) NA 
FIX NA 293.5 NA  NA NA NA 59.92 (12.5-125) NA 
control          
Pent - 7×10-4  (2×10-4-3×10-3) 6×10-5 (5×10-5 - 8×10-5)  - - - - - 
Doxo - - - 
 6.012 (0.8033-
45.00) 
10.3 (3.592-
29.55) 
4.302 (0.6804-
27.20) 
0.9881 (0.8213-
1.189) 
0.8919 (0.09391-
8.470) 
NT = No Tested; ND = No Determined; NA = No Active; Pent = Pentamidine; Doxo; Doxorrubicine; a confidence intervals in parenthesis.
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Table 3.3: 1D and 2D NMR data of compound C1 in CD3OD (
1H-NMR at 600 MHz; 13C-NMR at 150 
MHz) 
Residue Position δH mult.  
(J in Hz) 
δC gCOSY/TOCSY gHMBC 
Ala NH2 n/o*     
 1   176.8 (C)   
 2 4.36 q (7.11) 49.5 (CH) 3 1, 3, 1 (Ile1) 
 3 1.30 d (7.11) 18.2 (CH3) 2 1, 2 
 NH n/o*     
Ile1 1   171.2 (C)   
 2 4.84 d 61.4 (CH) 3, 4, 5, 6 1, 3, 4, 6, NMe, 1 (Ile2) 
 3 2.06 m 33.1 (CH) 2, 4, 5, 6  
 4 0.95/1.36 m 25.3 (CH2) 2, 3, 4 3, 5, 6 
 5 0.86 m 10.6 (CH3) 3, 4  
 6 0.92 d (5.64) 15.4 (CH3) 2, 3, 4  2, 3, 4 
 NMe 3.19 s 31.3  2, 1 (Ile2) 
Ile2 1   174.6 (C)   
 2 4.67 d (9.72) 54.1 (CH) 3, 4, 6 1, 3, 4, 6, 1 (Val1) 
 3 1.92 m 37.8 (CH) 2, 4, 6 2, 5, 6 
 4 1.16/1.52 m 25.5 (CH2) 2, 3, 5 2, 3, 5, 6 
 5 0.85 m 10.5 (CH3) 2, 3, 4 3, 4 
 6 0.87 d 14.9 (CH3) 2, 3, 4 2, 3 
 NH n/o*     
Val1 1   171.4 (C)   
 2 4.70 d (11.16) 63.0 (CH) 3, 4, 5 3, 4, 5, NMe 
 3 2.22 m 27.5 (CH) 2, 4, 5 2, 4, 5 
 4 0.76 d (6.54) 18.6 (CH3) 2, 3, 5 2, 3, 5 
 5 0.86 d 19.4 (CH3) 2, 3, 4 2, 3, 4 
 NMe 3.08 s 31.0  2, 1 (Val2) 
Val2 1   172.6 (C)   
 2 5.22 d (10.74) 59.6 (CH) 3, 4, 5 1, 3, 4, 5, NMe, 1 (Moya) 
 3 2.40 m 28.0 (CH) 2, 4, 5 2, 4, 5 
 4 0.93 d (5.64) 19.7 (CH3) 2, 3 2, 3, 5 
 5 0.87 d (6.24) 18.6 (CH3) 2, 3 2, 3, 4 
 NMe 3.04 s 30.8  2, 1 (Moya) 
Moya 1   179.1 (C)   
 2 2.89 m 37.0 (CH) 3, 4, 5, 6, 9 1, 3, 4, 9 
 3 1.39/1.72 m 34.3 (CH2) 2, 5, 6, 9 4, 5, 9 
 4 1.40 m 27.5 (CH2) 3, 5, 6 3, 5 
 5 1.50 m 29.4 (CH2) 2, 3, 4, 6, 9 3, 4, 6, 7 
 6 2.16 m 18.6 (CH2) 2, 3, 4, 5, 9 4, 5, 7, 8 
 7   84.5 (C)   
 8 n/o*  69.3 (CH)   
 9 1.08 d (6.78) 18.1 (CH3) 2, 3, 4, 5, 6 1, 2, 3 
* n/o = not observed. 
 
Substructure f spin system revealed this moiety as 2-methyl-oct-7-ynioc acid (Moya), a PKS-
derived moiety, by means of the HMBC correlations between C-7 (δC 84.5) and H2-5 and H2-6 
protons, and between C-8 (δC 69.3) and H2-6 methylene group, which confirms the alkyne 
terminal group previously mentioned, attached to the spin system showed in figure 3.3, which 
was determined by examination of 1H-1H correlations in gCOSY and TOCSY experiments.  
 
This triple bond terminus, is a characteristic feature in many cyanobacterial compounds including 
carbamin A [105], georgamide [106], pitipeptolide A [107], yanucamides [108], antanapeptins A 
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and D [109], trungapeptin A [110], hantupeptin A [111], wewakpeptins A and C [112], 
malevamide C [113], dragonamides C, D [114] and E [73], viridamides A and B [74] and 
veraguamides [103], and particularly this Moya moiety has been found with the two possible 
configurations in its stereocenter as (2S)-Moya in dragonamide A [115] dragonamide B, and 
dragomabine [73], and as (2R)-Moya in almiramide B [116]. 
 
Figure 3.4: Substructures a-f of compound C1 showing COSY/TOCSY and HMBC correlations. 
 
Interpretation of the HMBC correlations from the α-CH, β-H and N-methyl protons to carbonyl 
carbons allowed to establish unambiguously the linear sequence of substructures a-f for 
compound C1, and confirmed by HRESIMS fragmentation pattern, as show in figure 3.5. In the 
mass spectrum can be clearly seen the pseudomolecular ions [M+Na]+ at m/z 713.4906 and 
[M+H]+ at m/z 691.5092, and the sequential losses of each amino acid residue: [M-Ala]+ at m/z 
603.4456, [M-Ala-NMeIle]+ at m/z 476.3463, [M-Ala- NMeIle-Ile]+ at m/z 363.2628 and finally [M-
Ala- NMeIle-Ile-NMeVal1]+ at m/z 250.1793. 
Figure 3.5: Linear structure of C1 established from key HMBC correlations and HRESIMS 
fragmentation. 
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The structure of this compound is closely related to the series of almiramides lipopeptides 
previously isolated from a strain of L. majuscula collected from mangrove roots in Bocas del Toro 
Marine Park of Panamanian Caribbean Sea [116]. However this structure differs in the presence 
of isoleucine amino acid residues and in the NH2 terminus of the peptide which is an alanine 
residue. After careful revision of the literature in specialized data bases as Marinlit, Chemspider, 
Antibase and Scifinder we established that this structure has been not previously isolated from 
nature. Therefore this new compound is named almiramide D. Almiramides A-C were evaluated 
for their activity as antileishmanial agents, and served also for the development of semisynthetic 
analogues from which could be possible the identification of key structural features required for 
activity [116]. 
 
3.3.2. Structural elucidation of compound C2 
 
Compound C2 (3.7mg) was obtained as an optically active yellow amorphous solid with an [α]D 
value of -127.5 (c 0.3, MeOH), and a molecular formula of C40H64N6O6 as determined by HRESIMS 
(observed [M+Na]+ at m/z 747.4750, calculated [M+Na]+ 747.4785, and observed [M+H]+ at m/z 
725.4935, calculated [M+H]+ 725.4966). Analysis of 1H-NMR spectrum in CD3OD revealed the 
pattern of chemical shifts typical of peptides, corresponding to five α-methine proton signals at 
4.32, 4.52, 5.11, 5.30 and 5.46 ppm. Additionally to these signals, four sharp singlets at 2.11, 2.76, 
2.92 and 2.97 ppm showed the presence of four N-methyl groups, eight C-methyl groups, five 
methylenes, four aliphatic methines and 5 aromatic protons, for a total of 60 protons. Analysis of 
the phase-sensitive multiplicity-edited HSQC, of C2 showed the presence of the five α-methine 
protons at δC 50.2, 54.0, 57.7, 58.5 and 62.2ppm, additionally to six amide carbonyl signals 
between at δC 170.2, 170.8, 171.7, 172.2, 173.6 and 178.0. Carbon signals allowed confirming also 
the presence of four N-CH3, eight C-CH3 groups, five CH2, four CH and the aromatic ring, and 
carbon resonances at 83.2 and 68.1 ppm, showing the presence of an acetylenic terminal moiety, 
counting for the 40 carbons required according to the molecular formula (table 3.4). 
 
Table 3.4: 1D and 2D NMR data of compound C2 in CD3OD (
1H-NMR at 600 MHz; 13C-NMR at 150 
MHz) 
 
Residue Position δH mult.  
(J in Hz) 
δC gCOSY/TOCSY gHMBC 
Phe NH2 n/o*     
 1   173.6 (C)   
 2 5.46 dd (4.6, 12.4) 57.7 (CH) 3 1, 3, NMe 
 3 3.33/2.93 dd/m (4.8/15.0) 34.0 (CH2) 2 2, 4, 5 
 4   137.4 (C)   
 5 7.22 m 128.6 (CH) 6, 7 4, 6 
 6 7.18 m 128.4 (CH) 5, 7 5, 7 
 7 7.15 m 126.5 (CH) 5, 6 5 
 NMe 2.76 s 30.5 (CH3)  2, 1 (Ala) 
Ala 1   172.2 (C)   
 2 5.31 q (6.7) 50.2 (CH) 3 1, 3, NMe 
 3 1.01 d (6.7) 12.6 (CH3) 2 1, 2 
 NMe 2.11 s 28.8 (CH3)  2 
Val1 1   170.8 (C)   
 2 4.32 d (6.6) 54.0 (CH) 3, 4, 5 1, 3, 4 ,5 
 3 1.71 m 29.8 (CH) 2, 4, 5 4, 5 
 4 0.73 d (6.8) 16.3 (CH3) 2, 3 2, 3, 5 
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 5 0.76 d (6.9) 18.9 (CH3) 2, 3 2, 3 
 NH n/o*     
Val2 1   170.2 (C)   
 2 4.53 d (11.4) 62.2 (CH) 3, 4, 5 1, 3, 4, NMe, 1 (Val3) 
 3 2.12 m 26.2 (CH) 2, 4, 5 5 
 4 0.67 d (6.6) 17.8 (CH3) 2, 3 2, 5 
 5 0.77 d (6.6) 18.2 (CH3) 2, 3 2 
 NMe 2.97 s 30.0 (CH3)  1, 1(Val3) 
Val3 1   171.7 (C)   
 2 5.12 d (11.0) 58.5 (CH) 3, 4, 5 1, 3, 4, 5, NMe, 1 (Moya) 
 3 2.26 m 26.9 (CH) 2, 4 5 
 4 0.78 d (7.0) 17.5 (CH3) 2, 3 2, 5 
 5 0.83 d (6.6) 18.7 (CH3) 2, 3 2, 3, 4 
 NMe 2.92 s 29.6 (CH3)  2, 1 (Moya) 
Moya 1   178.0 (C)   
 2 2.79 m 35.9 (CH) 3, 5, 6, 9 3 
 3 1.63/1.30 m/m 33.1 (CH2) 2, 4, 5, 6, 9 2, 4, 5, 9 
 4 1.31 m 26.4 (CH2)  5 
 5 1.41 m 28.2 (CH2) 2, 3, 6, 9 3, 4, 6, 7 
 6 2.07 m 17.5 (CH2) 2, 3, 4, 5, 9 4, 5, 7, 8 
 7   83.2    
 8 n/o*  68.1   
 9 0.98 d (7.0) 16.9 (CH3) 2, 3, 4, 5, 6 1, 2, 3 
* n/o = not observed. 
 
Analysis of the 2D-NMR spectra allowed to identify six substructures (a-f) corresponding to 2-
methyl-8-octynoic acid, two N-methyl valines, one valine, one alanine and one N-methyl 
phenylalanine that accounted for all the atoms predicted by the molecular formula. gHMBC 
correlations made possible to identify the connectivity and sequence for some of the 
substructures elucidated as is shown in figure 3.6. 
 
N
N
N
O
O
1
3
5 7
1
3
b
a
 
Figure 3.6: Substructures a-f of compound C2 showing COSY/TOCSY and HMBC correlations. 
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Due to the lack of more HMBC correlations that allow the determination of the whole linear 
sequence forof C2, the MS data were used to establish it from the various possibilities derived 
from the three partial structures showed above. The sequence was established as Moya-NMe 
Val-NMe Val-Val-NMe Ala-NMe Phe and allowed to identify C2 as the previously reported 
almiramide B [116] (figure 3.7). 
 
Figure 3.7: Planar structure of C5 determined by HRESIMS fragmentation. 
 
3.3.3. Structural elucidation of compounds C3-C5 
 
Due to the minimal amounts obtained of compounds C3-C5, 1.3, 0.9 and 1.5 mg respectively, 
their structural elucidation by of NMR spectroscopic methods was not possible. However, its 
structure can be proposed on the basis of the HRESIMS data obtained for these compounds that 
allows to observe common structural features with the previously elucidated compounds C1 and 
C2. 
 
For C3, which was observed as one single peak in the HPLC chromatogram, the LC-MS profile 
revealed to be a mixture of two different compounds as can be seen by analysis of the TIC, which 
shows two different fragmentation patterns (figure 3.8). Analysis of the left part of TIC area 
reveals clearly the mass spectrum of one of the compounds, termed as C3.1, with a 
fragmentation pattern quite similar to those observed for almiramides C [116] and D, with an 
identical m/z ion at 250.1797 which indicates the presence of an NMe-valine residue linked to 
Moya moiety, as was observed for C1 and C2. Observed m/z peaks at 699.4764 and m/z 677.4945 
were indicative of [M+Na]+ and [M+H]+ peaks, respectively, that in addition to m/z at 589.4312 
were the most predominant in this TIC area. The MS-MS analysis of ion m/z 589.43 showed 
daughter ions at m/z 462.3312, 349.2477 and 250.1796 suggesting a similar fragmentation 
pattern to that for almiramide D, with a difference of just 14 u in the third fragmentation, 
suggesting the absence of the N-methyl Val1 residue, therefore indicating that C3.1 had the 
sequence Moya-NMe Val-Val-Ile-NMe Ile-Ala. The proposed structure for C3.1, after a revision in 
the above mentioned data bases, constitutes a new compound called almiramide E, showed in 
figure 3.9. Its structure was confirmed by the calculation of the m/z fragments, where the 
observed differences between the experimental and calculated fragments are less than 20 ppm 
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Figure 3.8: a. TIC obtained by LC-MS of C3; b. MS spectrum of C3.1; c. MS spectrum of C3.2. 
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Figure 3.9: Structure of almiramide E, deduced by MS fragmentation analysis. a in red calculated 
m/z fragments. b in blue experimental m/z fragments. 
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In the second area of C3 TIC, was observed the fragmentation pattern of a second compound 
different to that assigned for almiramide E. This second compound called almiramide F (C3.2) 
presents predominant m/z ions at 729.4866, 707.5048, 603.4465, 363.2633 and 250.1796. This 
proposal was confirmed by MS2 analysis of m/z 603.45, from which were obtained ions at 
476.3663, 363.2632 and 250.1796. With this fragmentation pattern, could be deduced that 
almiramide F had the sequence Moya-NMe Val2-NMe Val1-Ile-NMe Ile-Ser similar to that of 
almiramide D, except for a difference of +15.99 u in the first amino acid, suggesting the presence 
of an oxygen atom in this residue, allowing identifying this residue as serine. Again, the difference 
between obtained and calculated fragments did not exceed 20 ppm, which allowed proposing the 
structure indicated in figure 3.10. This structure was not previously reported in nature. 
 
Figure 3.10: Structure of almiramide F (C3.2) based on MS anaylisis. a in red calculated m/z 
fragments. b in blue obtained m/z fragments. 
 
As occurred with C3, C4 was initially believed to be one single compound by its HPLC purity 
profile. However, when subjected to LC-MS analysis, it was revealed to be a mixture of two 
different compounds. A predominant series of ions at m/z 699.4766, 677.4951, 589.4315, 
363.2637 and 250.1798 u was observed in the MS spectra for the first half TIC area. MS2 analysis 
of m/z 589.43 gave daughter ions at m/z 462.3316, 363.2634 and 250.1797. This compound 
(C4.1), had the sequence Moya-NMe Val1-NMeVal2 founded also in almiramide D, because of the 
fragments at m/z 363.2637 and 250.1798. In spite the difference in the molecular weight of C4.1 
and almiramide D, the difference between the ions at m/z 589.4315 and 462.3316 u suggest that 
the first two aminoacios are Ala and NMe Ile as in almiramide D. However, the difference 
observed with respect to almiramide D was the -14 u after the second amino acid fragmentation, 
suggesting that the Ile2 had been replaced by a valine residue, as shown in figure 3.11. This 
evidence allows proposing the structure for almiramide G, a compound previously unreported in 
nature. 
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Figure 3.11: MS analysis based structure for almiramide G (C4.1). a in red calculated m/z 
fragments.b in blue obtained m/z fragments. 
 
Almiramide H (C4.2) was proposed to be as showed in figure 3.12, because the fragmentation 
pattern observed in the MS and MS2 spectra, that showed to be identical to the obtained for 
almiramide D, with the same mass difference in the observed fragments, indicating the same 
linear sequence, except that each of the fragments present a mass 2 u lower, which led to 
propose that almiramide H possessed an additional insaturation in the terminal polyketide chain, 
this because of the characteristics of biosynthetic route of PKS in which is usual to found 
conjugated insaturations. Any of the proposed structures either with the double bond at C-3 or C-
5 also correspond to a new compound that also presents an excellent correlation between the 
observed and the calculated HRESIMS fragments. 
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Figure 3.12: Proposed structure for almiramide H. a in red calculated m/z fragments. b in blue 
obtained m/z fragments. 
 
TIC analysis for C5 showed a complex mixture of at least 3 different compounds, but just one 
cluster of fragments could be plenty identified by its MS fragmentation, leading to propose 
structure for almiramide I (C5.1) (figure 3.13). Again, this compound resembled mostly 
almiramide D structure, but there was a difference of -14 amu in the first amino acid released, 
which indicated that alaine residue had been replaced by glycine, and all the remaining sequence 
Moya-NMeVal2- NMe Val1- Ile2- NMe Ile1) conserved. 
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Figure 3.13: Structure of almiramide I by MS fragmentation analysis. a in red calculated m/z 
fragments. b in blue obtained m/z fragments. 
 
Compounds termed as C3.1, C3.2, C4.1, C4.2 and C5.1, constitute all new compounds, members 
of the almiramide class of cyanobacterial metabolites never previously reported in the literature. 
All these seven compounds found in sample of O. nigroviridis came from fraction FVII, which were 
one of the most toxic against A. salina and cytotoxic to murine macrophages, which permits to 
suppose that these compounds are the responsible ones for the toxic character of this specie. 
Interestingly all fraction FVII, was also the most active in the cytotoxicity assays which gives an 
indicative of a potential anticancer activity of these compounds, which would constitute in a new 
application of these type of cyanobacterial metabolites apart from the antileishmanial activity 
reported for some of them [116]. 
 
Neither almiramide B nor almiramide D were active in the antileishmania bioassay (table 3.5), 
they did not exert toxic effects on murine macrophages and activity against L. panamiensis 
promastigotes. Almiramide B, as previously reported [116] was highly active against L. donovani 
parasites which suggests a selective activity against this specie of Leishmania parasites, and also 
this assumption can be extended to all almiramide class of compounds, as in this published paper 
was found that one of the most important structural features of almiramides to be active is the 
presence of an alkyne terminus in conjunction with a high degree of N-methylation, which are 
found in almiramide D also. 
 
Table 3.5: Results of the evaluation of antileishmania activity of almiramides B and D. 
 
Compound Antileishmanial activity 
 Murine macrophages 
 LC50 (µg/mL)
a
 
L. panamiensis 
promastigotes  
EC50 (µg/mL)
a 
Almiramide B > 200 > 200 
Almiramide D > 200 > 200 
 
The absolute stereochemistry of compounds C4 and C5 has not been determined yet. In order to 
establish absolute configuration of the amino acids, implementation of Marfey’s method is now 
being carried out in our group. However, this is intended to be done only for both compounds, 
almiramide D and the known almiramide B, because of the sample amount and purity of 
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compounds. Also, we are actually working on the assignment of absolute configuration for C-2 at 
the of Moya moiety that can be present in R or S form as was previously discussed. 
 
As the major contributions of this work, may be considered in first instance the implementation 
of a technique for purification and isolation of non-ribosomal cyanobacterial peptides, leading for 
the first time in Colombia to carry out chemical studies on these promising and state-of-the-art 
microorganisms. This in turn helps to expand the bioprospection studies on marine sources of 
Colombia for their rational use in the search of pharmacological active molecules. This study 
allowed to the isolation and identification of the new molecule almiramide D, and to propose 
other five new compounds belonging to the almiramide class, together with the almiramide B. 
Together with the results of the studied sample, it is also to note the contribution with respect to 
the evaluation of bioactivity of crude extracts in which was demonstrated the potential to be 
source of anticancer compounds. 
 
  
 
4. Conclusions and recommendations 
4.1. Conclusions. 
By means of the Artemia salina lethality assay, the toxicity of 17 out of 27 marine cyanobacterial 
crude extracts was evaluated, finding that 12 out of the 17 crude extracts were highly toxic and 3 
were moderately toxic. These results indicate the predominance of toxic species in the 
cyanobacterial blooms of San Andres and Old Providence Islands. 
Based on the high toxicity displayed against A. salina, extracts labeled as PNM7, PNM10, PNM11 
and PNM14 were further evaluated in the anti-leishmanial bioassay, finding that none of them 
were active against parasites of Leishmania panamiensis, but were highly cytotoxic against 
murine macrophages with LC50 values all below 100 µg/mL. 
Evaluation of all 27 crude extracts against five human cancer cell lines, showed that with 
exception to extracts PNM1, PNM9, PNM12 and PNM21, all of the remaining extracts were active 
against at least one cancer cell line, mainly HeLa cellular line, with IC50 values ranging from <1 to 
~100 µg/mL. 
Because of its very low LC50 value in A. salina bioassay and sufficient amount of crude extract, 
sample PNM7 identified as Oscillatoria nigroviridis was subjected to brine shrimp bioassay and 
1H-NMR guided purification procedure, by means of which was possible to identify the active 
toxic fractions, comprised mainly by peptide-like compounds. 
From the identified active fractions was possible to isolate two principal compounds, the 
previously reported almiramide B and the new compound almiramide D. And based on structural 
similarities was also possible to identify 5 new compounds by MS and MS/MS analysis, which are 
also part of the almiramide class of compounds, named almiramide E, almiramide F, almiramide 
G, almiramide H and almiramide I. 
Neither almiramide B nor almiramide D were active against L. panamiensis, and taking into 
account the results from previous reported studies on this class of compounds which were active 
against L. donovani parasite, may suggest a selectivity of almiramides against this specific specie 
of Leishmania parasites. 
All the experimental work presented here allowed implementing a technique for the isolation and 
purification of non-ribosomal peptides from marine cyanobacteria. This in turn, constitutes the 
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first chemical study carried out in Colombia as source of new bioactive compounds, laying the 
basis for future work aimed to continue and spread this field in our country, contributing to the 
expansion of study of natural resources. 
4.2. Recommendations 
To avoid problems when making the chemical studies on the extracts, is recommended to start 
the culture of cyanobacterial mats, in order to obtained a sustainable source of extracts making 
possible to isolate enough amounts of pure compounds. 
It is recommended to evaluate the activity of crude extracts in a primary cell line such as human 
fibroblast, in order to determine if there is a selectivity of the extracts for the cancer cells which 
would establish the potential of this microorganisms for anticancer compounds, or if are just 
cytotoxic being not able to differentiate between normal and cancer cells. 
The absolute configuration has to be established, not only for the new compound almiramide D, 
but also for almiramide B, mainly for the stereocenter located at the fatty acid chain of 2-methyl 
octynoic acid, as this moiety has been found to be in both enantiomeric forms in different 
compounds, being possible to be opposite to that found for the almiramide B previously 
reported. 
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A. Appendix: Optic microscopy photograph of 
Oscillatoria nigroviridis filaments. 
 
Dominant morphotype in the sample corresponging to Oscillatoria nigroviridis. Details of the 
extremes of filaments are observed, as well as their width and length measures. Image taken at 
100x zoom by Julian Prato. 
 
  
 
B. Appendix: 
1
H-NMR profiles of fractions FVII6-
FVII8. 
 
1H-NMR spectrum of the fraction FVII6 recorded in CDCl3 at 400 MHz.  
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1H-NMR spectrum of the fraction FVII7 recorded in CDCl3 at 400 MHz. 
 
1H-NMR spectrum of the fraction FVII8 recorded in CDCl3 at 400 MHz. 
 
  
 
C. Appendix: NMR and MS spectra of almiramide D. 
 
1H-NMR spectrum of almiramide D taken in CD3OD at 400 MHz. 
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g-HSQC spectrum of almiramide D taken in CD3OD at 600 MHz. 
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g-COSY spectrum of almiramide D taken in CD3OD at 600 MHz. 
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g-TOCSY spectrum of almiramide D taken in CD3OD at 600 MHz. 
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g-HMBC spectrum of almiramide D taken in CD3OD at 600 MHz. 
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MS spectral data of almiramide D. a) HPLC chromatogram. b) TIC. c) MS spectra. d) MS fragmentation 
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D.Appendix: NMR and MS spectra of almiramide B. 
 
1H-NMR spectra of almiramide B taken in CDCl3 at 600 MHz. 
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g-HSQC spectrum of almiramide B taken in CD3OD at 600 MHz. 
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g-COSY spectrum of almiramide B taken in CD3OD at 600 MHz. 
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g-TOCSY spectrum of almiramide B taken in CD3OD at 600 MHz. 
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g-HMBC spectrum of almiramide B taken in CD3OD at 600 MHz. 
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MS spectral data of almiramide B. a) HPLC chromatogram. b) TIC. c) MS spectra. d) MS fragmentation. 
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